



(72) BOLANOWSKI, MARK A., US

(72) CAPARON, MAIRE H., US

(72) CASPERSON, GERALD F., US

(72) GREGORY, SUSAN A., US

(72) KLEIN, BARBARA K., US

(72) MCKEARN, JOHN P., US

(71) G.D. SEARLE & CO., US

(51) Int.Cl.⁷ C12N 15/62, C07K 14/78, C12N 9/68, A61K 48/00, C07K 14/56,
C07K 14/52, A61K 38/19, A61K 38/17


(30) 1997/10/01 (60/060,609) US

(54) **PROTEINES DE FUSION COMPRENANT UNE FRACTION
D'ANGIOSTATINE ET LEUR UTILISATION DANS UN
TRAITEMENT ANTI-TUMEUR**

(54) **FUSION PROTEINS COMPRISING AN ANGIOSTATIN MOIETY
AND THEIR USE IN ANTI-TUMOR TREATMENT**

Selected cloned angiotatin fragments containing kringle domains preceded by an
IL-3 signal peptide


Angiotatin fragments



(57) La présente invention concerne le développement de
nouvelles protéines multifonctionnelles (MFP)

(57) The present invention relates to the development
of novel multi-functional proteins (MFPs) of the





représentées par la formule $R_1-L_1-R_2$, $R_2-L_1-R_1$, $R_1-L_1-R_1$, R_1-R_2 , R_2-R_1 , ou R_1-R_1 . Dans cette formule, R_1 représente une angiostatine, R_2 est sélectionné dans le groupe constitué d'une endostatine, d'un interféron humain de type I, d'une thrombospondine, d'une protéine 10 inducible par l'interféron, d'un facteur plaquettaire 4 et L_1 représente une liaison capable de lier R_1 à R_2 . La présente invention concerne également des acides nucléiques qui codent des MFP, des procédures de fabrication de ces MFP, des procédés d'utilisation des MFP; des procédés de traitement de maladie à médiation angiogénique par des MFP comprenant des procédés de traitement de tumeurs par ces MFP et de traitement de tumeurs par une thérapie génique à l'aide de vecteurs qui codent les MFP.

formula: $R_1-L_1-R_2$, $R_2-L_1-R_1$, $R_1-L_1-R_1$, R_1-R_2 , R_2-R_1 , or R_1-R_1 where R_1 is angiostatin, R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10, platelet factor 4, and L_1 is a linker capable of linking R_1 to R_2 . The invention is also drawn to nucleic acids that encode MFPs, procedures for manufacturing MFPs, methods of using MFPs, methods of treating angiogenic-mediated disease with MFPs including methods of treating tumors with MFPs, and treating tumors by gene therapy using vectors that encode MFPs.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/62, 9/68, C07K 14/56, 14/78, 14/52, A61K 48/00, 38/17, 38/19	A1	(11) International Publication Number: WO 99/16889 (43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/US98/20464 (22) International Filing Date: 30 September 1998 (30.09.98) (30) Priority Data: 60/060,609 1 October 1997 (01.10.97) US (71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BOLANOWSKI, Mark, A. [US/US]; 5795 Shelton Drive, St. Charles, MO 63304 (US). CAPARON, Maire, H. [IE/US]; 109 Beechwood Court, Chesterfield, MO 63017 (US). CASPERSON, Gerald, F. [US/US]; 314 Claymont Drive, Ballwin, MO 63011 (US). GREGORY, Susan, A. [US/US]; 8136 Cornell Court, University City, MO 63130 (US). KLEIN, Barbara, K. [US/US]; 12917 Topping Estates, St. Louis, MO 63131 (US). McK-EARN, John, P. [US/US]; 18612 Babler Meadows Drive, Glencoe, MO 63038 (US). (74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FUSION PROTEINS COMPRISING AN ANGIOSTATIN MOIETY AND THEIR USE IN ANTI-TUMOR TREATMENT		
(57) Abstract The present invention relates to the development of novel multi-functional proteins (MFPs) of the formula: R₁-L₁-R₂, R₂-L₁-R₁, R₁-L₁-R₁, R₁-R₂, R₂-R₁, or R₁-R₁ where R₁ is angiostatin, R₂ is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10, platelet factor 4, and L₁ is a linker capable of linking R₁ to R₂. The invention is also drawn to nucleic acids that encode MFPs, procedures for manufacturing MFPs, methods of using MFPs, methods of treating angiogenic-mediated disease with MFPs including methods of treating tumors with MFPs, and treating tumors by gene therapy using vectors that encode MFPs. <u>Selected cloned angiostatin fragments containing kringle domains preceded by an IL-3 signal peptide</u> Angiostatin fragments		

FUSION PROTEINS COMPRISING AN ANGIOSTATIN MOIETY AND THEIR USE IN ANTI-TUMOR TREATMENT

Priority

The present application claims priority under Title 35, United States Code, § 119 of United States Provisional application Serial No. 60/060,609 filed October 2, 1997.

Field of the Invention

The present invention relates to the development of novel multi-functional proteins (MFPs) of the formula: $R_1-L_1-R_2$, $R_2-L_1-R_1$, $R_1-L_1-R_1$, R_1-R_2 , R_2-R_1 , or R_1-R_1 where R_1 is angiostatin, R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10, platelet factor 4, and L_1 is a linker capable of linking R_1 to R_2 . The invention is also drawn to nucleic acids that encode MFPs, procedures for manufacturing MFPs, methods of using MFPs, methods of treating angiogenic-mediated disease with MFPs including methods of treating tumors with MFPs, and treating tumors by gene therapy using vectors that encode MFPs.

Background of the Invention

Angiogenesis, the growth of new blood vessels, plays an important role in cancer growth and metastasis. In humans, the extent of vasculature in a tumor has been shown to correlate with the patient prognosis for a variety of cancers (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* **333**(26): 1757-1763, 1995; Gasparini, G., *European Journal of Cancer* **32A**(14): 2485-2493, 1996; Pluda, J. M., *Seminars in Oncology* **24**(2): 203-218, 1997). In normal adults, angiogenesis is limited to well controlled situations, such as wound healing and the female reproductive system (Battegay, E.J., *J Mol Med* **73**:333-346, 1995; Dvorak, H.F., *New Engl J Med*, **315**: 1650-1659, 1986).

Animal studies suggest that tumors can exist in a dormant state, in which tumor growth is limited by a balance between high rates of proliferation and high rates of apoptosis (Holmgren, L. et al., *Nat. Med. (N. Y.)* **1**(2): 149-153, 1995; Hanahan, D. et al., *Cell (Cambridge, Mass.)* **86**(3): 353-364, 1996). The switch to an angiogenic phenotype allows tumor cells to escape from dormancy and to grow rapidly, presumably as the result of a decrease in the apoptotic rate of the tumor

cells (Bouck, *Cancer Cells*, 2(6): 179-185, 1990; Dameron et al, *Cold Spring Harb Symp Quant Biol*, 59: 483-489, 1994). The control of angiogenesis is thought to be a balance between factors which promote new vessel formation and anti-angiogenic factors which suppress the formation of a neovasculature (Bouck, N. et al., *Advances in Cancer Research* 69: 135-173, 1996; O'Reilly et al., *Cell (Cambridge, Mass)* 79(2): 315-328, 1994).

A variety of pro-angiogenic factors have been characterized including basic and acid fibroblast growth factors (bFGF and aFGF) and vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) (Potgens, A. J. G. et al., *Biol. Chem. Hoppe-Seyler* 376: 57-70, 1995; Ferrara, N., *European Journal of Cancer* 32A(14): 2413-2442, 1996; Bikfalvi, A. et al., *Endocrine Reviews* 18: 26-45, 1997). Several endogenous anti-angiogenic factors have also been characterized, including angiostatin (O'Reilly et al., *Cell (Cambridge, Mass)* 79(2): 315-328, 1994), endostatin (O'Reilly et al, *Cell (Cambridge, Mass)* 88(2): 277-285, 1997), interferon alpha (Ezekowitz et al, *N. Engl. J. Med.*, May 28, 326(22) 1456-1463, 1992), thrombospondin (Good et al, *Proc Natl Acad Sci USA* 87(17): 6624-6628, 1990; Tolsma et al, *J Cell Biol* 122(2): 497-511, 1993), and platelet factor 4 (PF4) (Maione et al, *Science* 247:(4938): 77-79, 1990).

Angiostatin is a 38 kD protein comprising the first three or four kringle domains of plasminogen and was first described in 1994 (O'Reilly, M. S. et al., *Cell (Cambridge, Mass.)* 79(2): 315-328, 1994). Mice bearing primary (Lewis lung carcinoma-low metastatic) tumors did not respond to angiogenic stimuli such as bFGF in a corneal micropocket assay and the growth of metastatic tumors in these mice was suppressed until the primary tumor was excised. The factor responsible for the inhibition of angiogenesis and tumor growth was designated mouse angiostatin. Angiostatin was also shown to inhibit the growth of endothelial cells in vitro.

Human angiostatin can be prepared by digestion of plasminogen by porcine elastase (O'Reilly et al., *Cell* 79(2): 315-328, 1994) or with human metalloelastase (Dong et al., *Cell* 88, 801-810, 1997). The angiostatin produced via porcine elastase digestion inhibited the growth of metastases and primary tumors in mice. O'Reilly et al (*Cell* 79(2): 315-328, 1994) demonstrated that human angiostatin inhibited metastasis of Lewis lung carcinoma in SCID mice. The same group (O'Reilly, M. S. et al., *Nat. Med. (N. Y.)* 2(6): 689-692, 1996) subsequently showed that human angiostatin inhibited the growth of the human tumors PC3 prostate carcinoma, clone A colon carcinoma, and MDA-MB breast carcinoma in SCID mice. Human

angiostatin also inhibited the growth of the mouse tumors Lewis lung carcinoma, T241 fibrosarcoma and M5076 reticulum cell carcinoma in C57Bl mice. Because these enzymatically-prepared angiostatins are not well characterized biochemically, the precise composition of the molecules is not known.

5 Angiostatins of known composition can be prepared by means of recombinant DNA technology and expression in heterologous cell systems. Recombinant human angiostatin comprising Kringle domains one through four (K1-4) has been produced in the yeast *Pichia pastoris* (Sim et al., *Cancer Res* **57**: 1329-1334, 1997). The recombinant human protein inhibited growth of endothelial
10 cells in vitro and inhibited metastasis of Lewis lung carcinoma in C57Bl mice. Recombinant murine angiostatin (K1-4) has been produced in insect cells (Wu et al., *Biochem Biophys Res Comm* **236**: 651-654, 1997). The recombinant mouse protein inhibited endothelial cell growth in vitro and growth of primary Lewis lung carcinoma *in vivo*. These experiments demonstrated that the first four kringle
15 domains are sufficient for angiostatin activity but did not determine which kringle domains are necessary.

 Cao et al. (*J. Biol. Chem.* **271**: 29461-29467, 1996), produced fragments of human plasminogen by proteolysis and by expression of recombinant proteins in *E. coli*. These authors showed that kringle one and to a lesser extent kringle four of
20 plasminogen were responsible for the inhibition of endothelial cell growth in vitro. Specifically, kringles 1-4 and 1-3 inhibited at similar concentrations, while K1 alone inhibited endothelial cell growth at four-fold higher concentrations. Kringles two and three inhibited to a lesser extent. More recently Cao et al. (*J Biol Chem* **272**: 22924-22928, 1997), showed that recombinant mouse or human kringle five
25 inhibited endothelial cell growth at lower concentrations than angiostatin (K1-4). These experiments demonstrated in vitro angiostatin-like activity but did not address in vivo action against tumors and their metastases.

 World patent applications WO 95/29242 A1, WO 96/41194 A1, and WO 96/35774 A2 describe the expression, purification, and characterization of
30 angiostatin. WO 95/29242 A1 951102 discloses purification of a protein from blood and urine by HPLC that inhibits proliferation of endothelial cells. The protein has a molecular weight between 38 kilodaltons and 45 kilodaltons and an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 79 of a murine plasminogen molecule. WO
35 96/41194 A1 961219, discloses compounds and methods for the diagnosis and monitoring of angiogenesis-dependent diseases. WO 96/35774 A2 961114 discloses

the structure of protein fragments, generally corresponding to kringle structures occurring within angiostatin. It also discloses aggregate forms of angiostatin, which have endothelial cell inhibiting activity, and provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated diseases.

5 Endostatin, a 20-kDa (184 amino acid) carboxy fragment of collagen XVIII, is an angiogenesis inhibitor produced by a hemangioendothelioma (O'Reilly, M. S. et al., *Cell (Cambridge, Mass.)* 88(2): 277-285, 1997); and WO 97/15666). Endostatin specifically inhibits endothelial proliferation and inhibits angiogenesis and tumor growth. Primary tumors treated with non-refolded suspensions of *E.*
10 *coli*-derived endostatin regressed to dormant microscopic lesions. Toxicity was not observed and immunohistochemical studies revealed a blockage of angiogenesis accompanied by high proliferation balanced by apoptosis in tumor cells.

 Interferon alpha (IFN alpha) is a family of highly homologous, species-specific proteins that possess complex antiviral, antineoplastic and
15 immunomodulating activities (Extensively reviewed in the monograph "Antineoplastic agents, interferon alfa", American Society of Hospital Pharmacists, Inc., 1996). Interferon alpha also has anti-proliferative, and anti-angiogenic properties, and has specific effects on cellular differentiation (Sreevalsan, in "Biologic Therapy of Cancer", pp. 347-364, (eds. V.T. DeVita Jr., S. Hellman, and
20 S.A. Rosenberg), J.B. Lippincott Co, Philadelphia, PA, 1995).

 Interferon alpha is effective against a variety of cancers including hairy cell leukemia, chronic myelogenous leukemia, malignant melanoma, and Kaposi's sarcoma. The precise mechanism by which IFN alpha exerts its anti-tumor activity is not entirely clear, and may differ based on the tumor type or stage of
25 disease. The anti-proliferative properties of IFN alpha, which may result from the modulation of the expression of oncogenes and/or proto-oncogenes, have been demonstrated on both tumor cell lines and human tumors growing in nude mice (Gutterman, J. U., *Proc. Natl. Acad. Sci., USA* 91: 1198-1205, 1994).

 Interferon is also considered an anti-angiogenic factor, as demonstrated
30 through the successful treatment of hemangiomas in infants (Ezekowitz et al, *N. Engl. J. Med.*, May 28, 326(22) 1456-1463, 1992) and the effectiveness of IFN alpha against Kaposi's sarcoma (Krown, *Semin Oncol* 14(2 Suppl 3): 27-33, 1987). The mechanism underlying these anti-angiogenic effects is not clear, and may be the result of IFN alpha action on the tumor (decreasing the secretion of pro-angiogenic
35 factors) or on the neo-vasculature. IFN receptors have been identified on a variety

of cell types (Navarro et al., *Modern Pathology* 9(2): 150-156, 1996).

United States Patent 4,530,901, by Weissmann, describes the cloning and expression of IFN-alpha-type molecules in transformed host strains. United States Patent 4,503,035, Pestka, describes an improved processes for purifying 10 species
5 of human leukocyte interferon using preparative high performance liquid chromatography. United States Patent 5,231,176, Goeddel, describes the cloning of a novel distinct family of human leukocyte interferons containing in their mature form greater than 166 and no more than 172 amino acids.

United States Patent 5,541,293, by Stabinsky, describes the synthesis,
10 cloning, and expression of consensus human interferons. These are non-naturally occurring analogues of human (leukocyte) interferon-alpha assembled from synthetic oligonucleotides. The sequence of the consensus interferon was determined by comparing the sequences of 13 members of the IFN-alpha family of interferons and selecting the preferred amino acid at each position. These
15 variants differ from naturally occurring forms in terms of the identity and/or location of one or more amino acids, and one or more biological and pharmacological properties (e.g., antibody reactivity, potency, or duration effect) but retain other such properties.

Thrombospondin-1 (TSP-1) is a trimer containing three copies of a 180 kDa
20 polypeptide. TSP-1 is produced by many cell types including platelets, fibroblasts, and endothelial cells (see Frazier, *Curr Opin Cell Biol* 3(5): 792-799, 1991) and the cDNA encoding the subunit has been cloned (Hennessy et al., 1989, *J Cell Biol* 108(2): 729-736; Lawler and Hynes, *J Cell Biol* 103(5): 1635-1648, 1986). Native TSP-1 has been shown to block endothelial cell migration *in vitro* and
25 neovascularization *in vivo* (Good et al, *Proc Natl Acad Sci USA* 87(17): 6624-6628, 1990). Expression of TSP-1 in tumor cells also suppresses tumorigenesis and tumor-induced angiogenesis (Sheibani and Frazier, *Proc Natl Acad Sci USA* 92(15) 6788-6792, 1995; Weinstat-Saslow et al., *Cancer Res* 54(24):6504-6511, 1994). The anti-angiogenic activity of TSP-1 has been shown to reside in two distinct domains
30 of this protein (Tolsma et al, *J Cell Biol* 122(2): 497-511, 1993). One of these domains consists of residues 303 to 309 of native TSP-1 and the other consists of residues 481 to 499 of TSP-1. Another important domain consists of the sequence CSVTCG which appears to mediate the binding of TSP-1 to some tumor cell types (Tuszynski and Nicosia, *Bioessays* 18(1): 71-76, 1996). These results suggest that
35 CSVTCG, or related sequences, can be used to target other moieties to tumor cells. Taken together, the available data indicate that TSP-1 plays a role in the growth

and vascularization of tumors. Subfragments of TSP-1, then, may be useful as anti-angiogenic components of chimeras and/or in targeting other proteins to specific tumor cells. Subfragments may be generated by standard procedures (such as proteolytic fragmentation, or by DNA amplification, cloning, expression, and purification of specific TSP-1 domains or subdomains) and tested for anti-angiogenic or anti-tumor activities by methods known in the art (Tolsma et al, *J Cell Biol* **122**(2): 497-511, 1993; Tuszynski and Nicosia, *Bioessays* **18**(1): 71-76, 1996).

A variety of *in vivo* experiments demonstrate that chemokines platelet factor 4 (PF-4) and interferon inducible protein 10 (IP-10) retard the growth of tumors. PF-4 blocks the growth of primary tumors in mice (mouse melanoma and human colon cancer) (Sharpe et al., *J. Natl. Cancer Inst.* **82**, 848-853; Maione et al. *Cancer Res.* **51**, 2077-2083, 1991). IP-10 administration blocks non-small cell lung tumorigenesis and Burkitt's lymphoma subcutaneous tumors in mice (Arenberg et al., *J. Exp. Med.* **184**, 981-992, 1996; Sgardari et al. *Proc. Natl. Acad. Sci. USA* **93**, 13791-13796, 1996). PF-4 is currently in clinical trials for Kaposi's sarcoma, glioblastoma, melanoma, renal cell and colon cancer. IP-10 promotes the migration of activated lymphocytes to the site of injection thereby suggesting that IP-10 may have immuno-modulatory properties. The immuno-modulatory property may contribute to the anti-tumor capacity of IP-10.

Anti-angiogenic therapy may offer several advantages over conventional chemotherapy for the treatment of cancer. Anti-angiogenic agents have low toxicity in preclinical trials and development of drug resistance has not been observed (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* **333**(26): 1757-1763, 1995). As angiogenesis is a complex process, made up of many steps including invasion, proliferation and migration of endothelial cells, it can be anticipated that combination therapies may be most effective. In fact, combinations of chemotherapy with anti-angiogenic therapy have already shown promising results in pre-clinical models (Teicher, B. A. et al., *Breast Cancer Research and Treatment* **36**: 227-236, 1995; Teicher, B. A. et al., *European Journal of Cancer* **32A**(14): 2461-2466, 1996).

Chimeras of angiostatin with other anti-angiogenic proteins such as endostatin may have improved biological properties by virtue of acting through several mechanisms. The two proteins may have distinct mechanisms, allowing increased efficacy by virtue of blocking the angiogenic process at two separate points. Alternatively, the two proteins may act on the same cell type causing an

increased binding, or other action, by virtue of increased avidity. In this case, each molecule would also have the effect of targeting the other domain to the appropriate site of action. Dimers or higher order multimers of angiostatin, endostatin, or other anti-angiogenic proteins with themselves or other proteins
5 could have increased efficacy and/or potency by virtue of either of these mechanisms.

One class of mechanisms for improved activity of angiostatin chimeras would result from the ability to bind to two distinct receptors on the same cell (e.g., receptor agonists) and thus demonstrate improved activity due to interactions with
10 receptors on a single cell. These chimeras may have improved therapeutic properties through a variety of mechanisms such as: 1). alterations in the overall on- or off-rates or K_a or K_d of the ligand(s) on the target cell, 2). activation or blockade of complementary receptor signaling pathways, and/or 3). more specific targeting of one or both of the components to the cell of interest. Examples of this
15 class are endothelial cell binding dual receptor agonists (or antagonists) such as: A_vB_3 -angiostatin, angiostatin-IP-10, and angiostatin-IFN alpha. For example, formation of a chimera between angiostatin and a non-ELR-C-X-C chemokine is expected to generate a receptor agonist which has anti-angiogenic effects on the endothelium. In addition, an IP-10-angiostatin chimera would be expected to
20 contain an immunomodulatory component affecting the recruitment of white blood cells to the tumor. IP-10 would also be expected to have an effect on the primary tumor and on metastasis. Further, the chimeric proteins are expected to possess a unique pharmacokinetic distribution and clearance profile (Dehmer et al. *Circulation*, **91**, 2188-2194, 1995; Tanaka et al. *Nature Medicine*, **3**, 437-442, 1997).

25 A second class of mechanisms does not depend on receptor binding on the same cell, but where the chimeric protein has improved properties *in vivo* compared to the two components individually. This may be a result of alterations in biodistribution or half-life. Alternatively, the binding of the chimera to one or more of the receptors, pharmacokinetics, or uptake of the chimera is altered in a
30 favorable manner. These proteins are likely to act through complementary mechanisms. Therefore, chimeric proteins containing anti-proliferative and anti-angiogenic activities may provide improved anti-tumor activity by using two distinct mechanisms to decrease tumor growth. The anti-proliferative moiety should act directly on the tumor to decrease its growth while the anti-angiogenic
35 factor should act indirectly by preventing the growth of the neo-vasculature required for rapid tumor growth. One example of this mechanism might include angiostatin/IFN alpha chimeras.

Summary of the Invention

Novel proteins of this invention are represented by the formulas:



wherein R_1 is a modified human angiostatin amino acid sequence,

5 and R_2 is a modified endostatin, human type I interferon, thrombospondin or a fragment thereof, interferon-inducible protein 10, platelet factor 4, and proteins with similar activity,

and wherein L_1 is a linker capable of linking R_1 to R_2 ,

10 and said protein can optionally be immediately preceded by (methionine⁻¹), (alanine⁻¹), (methionine⁻², alanine⁻¹), (serine⁻¹), (methionine⁻², serine⁻¹), (cysteine⁻¹), or (methionine⁻², cysteine⁻¹).

Preferably, R_1 is selected from the from the group consisting of angiostatin K1, angiostatin K5, angiostatin K1-K3, angiostatin K1-K4, or a functional homologue thereof.

15 Preferably R_2 is selected from the from the group consisting of interferon alpha A/D and interferon alpha 2b.

Even more preferably, R_2 is selected from the group consisting of interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, type I interferon variants, and consensus interferon, or a functional homologue or variant protein thereof.

20

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional proteins, related microbial and eukaryotic expression systems, and processes for making the multi-functional proteins. The invention also relates to pharmaceutical compositions containing the multi-functional proteins, and methods for using the multi-functional proteins.

25

Definitions

The term "multi-functional protein" means a single polypeptide which inherently possesses two distinct activities. In the context of the current invention,

anti-angiogenic and/or anti-tumor activities are contemplated. The polypeptide may be formed by the covalent union of two distinct proteins or portions thereof, or two copies of the same protein, or portions thereof.

5 The term "anti-tumor" means possessing an activity which slows or abolishes the growth of, or which kills, or otherwise harms tumors *in vivo*.

The term "native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

10 The terms "mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refer to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid additions, deletions, substitutions, or all three, or is encoded by a nucleotide sequence from an intentionally-made variant derived from a native sequence.

15 The term "angiostatin" means a protein fragment of the heavy chain (SEQ ID NO: 37) of plasminogen having anti-angiogenic activity. The activity of said fragments can be determined by the mouse corneal micropocket assay of angiogenesis or by inhibition of endothelial cell growth *in vitro*.

20 The term "kringle" or "K" means a fragment or substructure of plasminogen or angiostatin bounded by disulfide-linked cysteine residues, and which retain a structure similar to that which it will adopt within the whole of plasminogen. A kringle domain may also include interkringle sequences which serve to connect it with other kringle domains. The terms K1, K2, K3, K4, K5 refer to specific kringle domains, and terms like K1-3 or K2-4, for example, refer to contiguous protein segments from the first kringle through the last kringle in a series, including the interkringle sequences.

25 The term "interferon" includes one of a group of proteins having anti-viral and anti-tumor activities including type I interferon, type I interferon variants, interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, consensus interferon, functional homologues thereof, and those encoded by a DNA sequences related to those in SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID
30 NO: 31.

The term "thrombospondin" means the proteins identical or essentially identical to thrombospondin and internal fragments of thrombospondin which possess anti-angiogenic activity.

Brief Description of the Figures

Figure 1 shows a schematic of selected cloned angiostatin fragments containing kringle domains preceded by an IL-3 signal peptide

5 The labels K1, K2, K3, K4, and K5, refer to specific kringle domains within human plasminogen or angiostatin. Plasmid pMON24624 contains the sequence of the heavy chain of human plasminogen including the N-terminal peptide (NTP) and the signal peptide (SP). Plasmids pMON24625 (K1-K4), pMON24626 (K1-K3), pMON24627 (K2-K4), pMON24628 (K2-K3), and pMON24650 (K1), each contain various kringle domains, preceded by the IL-3 signal peptide (IL3). These
10 plasmids also contain sequences necessary for expression and secretion of the proteins from mammalian (e.g., BHK) cells.

Figure 2 shows a schematic of selected cloned angiostatin fragments containing kringle domains

15 The plasmid pMON24642 encodes kringles K1-K4 plus additional human plasminogen sequences at its 5' and 3' ends shown in the diagram by solid areas. Plasmids pMON24643 (K1-K4), pMON24644 (K2-K3), pMON24645 (K2-K3), pMON24646 (K1-K3), and pMON24648 (K1) contain specific kringle domains of human plasminogen. These plasmids also contain sequences necessary for the expression of the encoded polypeptides in *E. coli*.

20 **Figure 3 shows a schematic of selected angiostatin/interferon alpha 2b chimeric fusion proteins**

Plasmid pMON20413 encodes the K1 kringle domain fused to interferon alpha through a Glycine-Serine (Gly-Ser) linker peptide. Plasmid pMON20414 is similar to PMON20413, but encodes a chimeric fusion protein containing interferon
25 alpha at its N-terminus fused to the Gly-Ser linker, which is fused to the K1 kringle domain of plasminogen (angiostatin). Plasmid pMON20416 encodes a fusion protein consisting of kringle domains K1-K3 fused to interferon alpha with a Gly-Ser linker.

30 **Figure 4 shows a schematic of selected angiostatin/interferon alpha A/D chimeric fusion proteins**

Plasmid pMON20412 encodes kringles K1-K3 fused to the hybrid A/D interferon with a Gly-Ser linker. Plasmid pMON20420 encodes a fusion protein

containing the hybrid A/D interferon fused to kringles K1-K3 through a Gly-Ser linker. Plasmid pMON20421 encodes kringle K1 fused to the hybrid A/D interferon with a Gly-Ser linker. Plasmid pMON20422 encodes a fusion protein containing the hybrid A/D interferon fused to kringle K1 through a Gly-Ser linker.

5 **Figure 5 shows the proliferation of Daudi cells in the presence of interferon A/D and an interferon A/D K1-3 angiostatin chimeric protein**

Two replicates of assays depicting the proliferation of Daudi cells in the presence of interferon A/D (standard, from Genzyme) and an interferon A/D K1-3 angiostatin chimeric protein are shown. Protein samples were serially diluted, beginning at a concentration of 1 mM.

10






Detailed Description of the Invention

The present invention encompasses multi-functional proteins (MFPs) which inherently possess two distinct activities. In the context of this invention, anti-angiogenic and/or anti-tumor activities are contemplated. The polypeptide may be formed by the covalent union of two distinct proteins, or portions thereof. Each distinct protein segment which may act through a different and specific cell receptor to initiate complementary biological activities. The MFPs may also be formed from covalently-linked polypeptides derived from the same protein.

15

Peptide-bonded chimeric fusion proteins

20 Novel compounds of this invention are represented by a formula selected from the group consisting of:



Where R_1 and R_2 are as defined above.

R_2 is preferably a protein or protein fragment with a different but complementary activity than R_1 . Complementary activity is meant to be activity which enhances or changes the response to another cell modulator. The R_1 polypeptide is joined either directly or through a linker segment to the R_2 polypeptide. The term "directly" defines multi-functional proteins in which the polypeptides are joined without a peptide linker. Thus L_1 represents a chemical bond or polypeptide segment to which both R_1 and R_2 are joined in frame. Most commonly L_1 is a linear peptide in which R_1 and R_2 are joined by amide bonds, linking the carboxy terminus of R_1 to the amino terminus of L_1 and carboxy terminus of L_1 to the amino terminus of R_2 . "Joined in frame" means that there is no translation termination or disruption between the reading frames of the DNA encoding R_1 and R_2 .

Additionally, this invention encompasses the use of modified R_1 or R_2 molecules or mutated or modified DNA sequences encoding these R_1 or R_2 molecules. The present invention also includes multi-functional proteins in which R_1 or R_2 is a variant.

The linking group (L_1) is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic characteristics which could interact with the functional protein domains and (4) provide steric separation of R_1 and R_2 such that R_1 and R_2 could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional proteins.

Preferred L_1 linkers of the present invention include sequences selected from the group of formulas:

$(\text{Gly}^3\text{Ser})^n$ (SEQ ID NO. 88),
 $(\text{Gly}^4\text{Ser})^n$ (SEQ ID NO. 89),

(Gly⁵Ser)ⁿ (SEQ ID NO. 90),
 (GlyⁿSer)ⁿ (SEQ ID NO. 92) or
 (AlaGlySer)ⁿ (SEQ ID NO. 91).

One example of a highly-flexible linker is the glycine and serine-rich spacer
 5 region present within the pIII protein of the filamentous bacteriophages, e.g.
 bacteriophages M13 or fd (Schaller et al., *PNAS USA* 72: 737-741, 1975). This
 region provides a long, flexible spacer region between two domains of the pIII
 surface protein. The spacer region consists of the amino acid sequence:

10 GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGlu
 GlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO. 93)

The present invention also includes linkers in which an endopeptidase
 recognition sequence is included. Such a cleavage site may be valuable to separate
 the individual components of the multi-functional protein to determine if they are
 15 properly folded and active *in vitro*. Examples of various endopeptidases include,
 but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue
 plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom
 protease, post-proline cleavage enzyme, V8 protease, Thrombin and factor Xa.

Peptide linker segments from the hinge region of heavy chain
 20 immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship
 between the attached polypeptides. Especially useful are those hinge regions where
 the cysteines are replaced with serines. Preferred linkers of the present invention
 include sequences derived from murine IgG gamma 2b hinge region in which the
 cysteines have been changed to serines. These linkers may also include an
 25 endopeptidase cleavage site. Examples of such linkers include the following
 sequences:

IleSerGluProSerGlyProIleSerThrIleAsnProSerProProSerLys
 GluSerHisLysSerPro (SEQ ID NO. 94) and
 30 IleGluGlyArgIleSerGluProSerGlyProIleSerThrIleAsnProSer
 ProProSerLysGluSerHisLysSerPro (SEQ ID NO. 95).

The present invention is, however, not limited by the form, size or number
 of linker sequences employed. The only requirement of the linker is that it does
 35 not functionally interfere with the folding and function of the individual molecules
 of the multi-functional protein.

Additional peptide sequences may also be added to facilitate purification or
 identification of multi-functional proteins (e.g., poly-His). A highly antigenic

peptide may also be added that would enable rapid assay and facile purification of the multi-functional protein by a specific monoclonal antibody.

Multi-functional proteins of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional proteins which have little or no activity maybe useful as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful muteins.

Biological activity of the multi-functional proteins of the present invention can be determined by tumor cell proliferation assays, endothelial cell proliferation assays, endothelial cell migration assays, endothelial cell tube formation assays, mouse corneal micro-pocket angiogenesis assays, and tumor growth assays. Syngeneic models of mouse tumor growth, such as the Lewis Lung carcinoma assay (Sugiura and Stock, *Cancer Res.*, **15**: 38-51, 1955; O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994), and xenograft models of human tumors in nude or SCID mice using human breast cancer, prostate carcinoma, or melanoma cell lines are also used (Price, *Breast Cancer Research and Treatment*, **39**: 93-102, 1996; Sasaki et al., *Can. Res.* **55**: 3551-3557, 1995; Pretlow et al, *Can. Res.* **51**: 3814-3817, 1991 and Passaniti et al., *Int. J. Cancer*, **51**: 318-324, 1992; Felding-Habermann et al., *J. Clin. Invest.*, **89**: 2018-2022, 1992).

The biological activity of individual protein subunits can be performed using specific assays. The antiviral activity of interferon, for example, can be carried out by titering the potency of interferon preparations on Madin Darby bovine kidney cells infected with vesicular stomatitis virus (Rubinstein et al., *J. Virol.* **37**(2): 755-758, 1981).

The multi-functional proteins of the present invention may have an improved therapeutic profile as compared to single-acting anti-angiogenic or anti-tumor proteins. For example, some multi-functional proteins of the present invention may have a similar or more potent anti-tumor activity relative to other anti-tumor proteins without having a similar or corresponding increase in side-effects.

Therapeutic targets

The multi-functional proteins of the present invention may be useful in the treatment of angiogenic-mediated diseases such as cancer, diabetic retinopathy, and macular degeneration. Among the cancers susceptible to treatment with the polypeptides of the present invention are lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.

The present invention provides an improvement to the existing methods of treating solid tumors, in that it provides methods utilizing multi-functional proteins that have improved biological activities. Therapeutic treatment of tumors with these multi-functional proteins of the present invention may avoid undesirable side effects caused by treatment with presently available drugs. The treatment of solid tumors may include administration of a pharmaceutical composition containing the multi-functional proteins to a patient.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional proteins of the present invention in a mixture with a pharmaceutically acceptable carrier. The compositions can also be admixtures containing adjunctive agents, such as chemotherapeutic or immunotherapeutic agents. This composition can be administered either parenterally, intravenously, or subcutaneously. Other routes of administration are also contemplated, including intranasal and transdermal routes, and by inhalation. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally-acceptable aqueous solution. The preparation of such a parenterally-acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g., the condition, body weight, sex, and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be about 1.0 µg/kg of multi-functional proteins per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multi-functional proteins and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1

microgram and as high as 100 milligrams per kilogram of body weight per day.

5 In addition, there may exist specific circumstances where dosages of multi-functional proteins would be adjusted higher or lower than the range of 0.2 - 100,000 micrograms per kilogram of body weight. These include co-administration with other anti-angiogenic or antitumor proteins or variants; co-administration with adjunctive agents such as chemotherapeutic or immunotherapeutic agents, co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional proteins; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and
10 compositions may also include co-administration with other human anti-tumor proteins.

A non-exclusive list of other appropriate anti-angiogenic or anti-tumor agents or treatments includes chemotherapy, radiation therapy, hormonal therapy, or interleukin-2, or combinations thereof. The dosage recited above would be
15 adjusted to compensate for such additional components in the therapeutic composition.

Delivery of multi-functional proteins to a patient could also be performed through gene therapy. There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both
20 viral and non-viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include; 1) replication deficient recombinant retrovirus (Boris-Lawrie and Temin, *Curr. Opin. Genet. Dev.* 3:102-109, 1993, Boris-Lawrie and Temin, *Annal. New York Acad. Sci.* 716:59-71, 1994, Miller, *Current Top. Microbiol. Immunol.* 158:1-24, 1992) and replication-deficient
25 recombinant adenovirus (Berkner, *BioTechniques* 6:616-629, 1988, Berkner, *Current Top. Microbiol. Immunol.* 158:39-66, 1992, Brody and Crystal, *Annal. New York Acad. Sci.* 716:90-103, 1994). Non-viral based vectors include protein/DNA complexes (Cristiano et al., *PNAS USA.* 90:2122-2126, 1993, Curiel et al., *PNAS USA* 88:8850-8854, 1991, Curiel, *Annal. New York Acad. Sci.* 716:36-58, 1994),
30 electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., *Annal. New York Acad. Sci.* 716:23-35, 1994).

Cloning and expression of genes encoding multi-functional proteins

The present invention also includes the DNA sequences which code for the multi-functional proteins, DNA sequences which are substantially similar and

perform substantially the same function, and DNA sequences which differ from the DNAs encoding the multi-functional proteins of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides.

Genetic engineering techniques now standard in the art (United States Patent 4,935,233 and Sambrook et al., "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al., *Gene* 34:315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites.

Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent *E. coli* cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of DNA sequences encoding novel multi-functional proteins may be accomplished by the use of intermediate vectors. Alternatively, one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism or cell line is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has all or a portion of one protein joined by a linker region to a all or a portion of second protein.

Another aspect of the present invention includes plasmid DNA vectors for use in the expression of these novel multi-functional proteins. These vectors contain the novel DNA sequences described above which code for the novel

polypeptides of the invention. Appropriate vectors which can transform microorganisms or cell lines capable of expressing the multi-functional proteins include expression vectors comprising nucleotide sequences coding for the multi-functional proteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional proteins. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

Methods for producing the novel multi-functional proteins is another aspect of the present invention. The method of the present invention involves culturing suitable cells or cell lines, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional protein. Suitable cells or cell lines may be bacterial cells. For example, the various strains of *E. coli* are well-known as host cells in the field of biotechnology. Examples of such strains include *E. coli* strains JM101 (Yanisch-Perron et al. *Gene* 33: 103-119, 1985) and MON105 (Obukowicz et al., *Applied Environmental Microbiology* 58: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional proteins utilizing a chromosomal expression vector for *E. coli* based on the bacteriophage Mu (Weinberg et al., *Gene* 126: 25-33, 1993). Various strains of *B. subtilis* may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.

When expressed in the *E. coli* cytoplasm, the gene encoding the multi-functional proteins of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met²-Ala¹, Met²-Ser¹, Met²-Cys¹, or Met¹ at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of *E. coli* are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., *J. Bacteriol.* 169:751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional proteins of the present invention may include multi-functional proteins polypeptides having Met¹, Ala¹, Ser¹, Cys¹, Met²-Ala¹, Met²-Ser¹, or Met²-Cys¹ at the N-terminus. These mutant multi-functional proteins may also be expressed in *E. coli* by fusing a secretion signal peptide to the

N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process.

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary (CHO) cells. General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. J., 1987, "Genetic Engineering, Principles and Methods", Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional proteins. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, California) can be used. The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al., *Proc. Natl. Acad. Sci. USA* 84: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells such as the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24 - 72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, *Nature*, 293:620-625, 1981, or alternatively, Kaufman et al, *Mol. Cell. Biol.*, 5(7):1750-1759, 1985) or Howley et al., and U.S. Pat. No. 4,419,446. Other suitable mammalian cell lines are the monkey COS-1 cell line and the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g., Luckow, V.A., *Protein Eng.* J. L. Cleland., Wiley-Liss, New York, NY: 183-218, 1996 and references cited therein. In addition, general methods for expression of foreign genes in insect cells using baculovirus vectors are described in: O'Reilly, D. R., L. K. Miller et al. *Baculovirus Expression Vectors: A Laboratory Manual*. New York, W.H. Freeman and Company, 1992, and King, L. A. and R. D. Possee, *The Baculovirus Expression System: A Laboratory Guide*, London, Chapman & Hall. An expression vector is constructed comprising a baculovirus transfer vector, in which a strong baculovirus promoter (such as the polyhedrin promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-

functional protein. For example, the plasmid pVL1393 (obtained from Invitrogen Corp., San Diego, California) can be used. After construction of the vector carrying the gene encoding the multi-functional protein, two micrograms of this DNA is co-transfected with one microgram of baculovirus DNA into *Spodoptera frugiperda* insect cells, strain Sf9. Alternatively, recombinant baculoviruses can be created using a baculovirus shuttle vector system (Luckow, V.A. et al., *J. Virol.* **67**(8): 4566-4579, 1993) now marketed as the Bac-To-Bac™ Expression System (Life Technologies, Inc. Rockville, MD). Pure recombinant baculovirus carrying the multi-functional protein is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kansas) or Sf900-II (Life Technologies, Inc.). The multi-functional protein secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional proteins can be first concentrated using any of a number of commercial concentration units.

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples. Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

Materials and Methods

General methods

General methods of cloning, expressing, and characterizing proteins are found in T. Maniatis et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982, and references cited therein, incorporated herein by reference; and in J. Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory, 1989, and references cited therein, incorporated herein by reference.

Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, MO). Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN).

Transformation of E. coli strains

E. coli strains (Table 1), such as DH5 α TM (Life Technologies, Gaithersburg, MD) and TG1 (Amersham Corp., Arlington Heights, IL) are used for transformation of ligation reactions and are the hosts used to prepare plasmid DNA for transfecting mammalian cells. *E. coli* strains, such as JM101 (Yanisch-Perron et al., *Gene*, 33: 103-119, 1985) and MON105 (Obukowicz et al., *Appl. and Envir. Micr.*, 58: 1511-1523, 1992) can be used for expressing the multi-functional proteins of the present invention in the cytoplasm or periplasmic space.

TABLE 1 Strains

Designation	Description	Reference/Source
DH5 α TM	F ⁻ , <i>phi80 dlacZdeltaM15</i> , <i>delta(lacZYA-argF)U169</i> , <i>deoR</i> , <i>recA1</i> , <i>endA1</i> , <i>hsdR17</i> (rk ⁻ ,mk ⁺), <i>phoA</i> , <i>supE44</i> , <i>lambda-</i> , <i>thi-1</i> , <i>gyrA96</i> , <i>relA1</i>	Life Technologies, Rockville, Maryland
JM101 (ATCC#33876)	<i>delta (pro lac)</i> , <i>supE</i> , <i>thi</i> , F'(<i>traD36</i> , <i>proA</i> ⁺ <i>B</i> ⁺ , <i>lacI</i> ^q , <i>lacZdeltaM15</i>)	Yanisch-Perron et al., <i>Gene</i> , 33: 103-119, 1985
MON105 (ATCC#55204)	F ⁻ , <i>lambda-IN</i> (<i>rrnD</i> , <i>rrnE</i>)1, <i>rpoD</i> ⁺ , <i>rpoH358</i>	Obukowicz et al., <i>Appl. and Envir. Micr.</i> , 58: 1511-1523, 1992
MON208	W3110 <i>rpoH358</i> , <i>lacI</i> ^q , <i>ompT::kan</i>	Alan Easton, Monsanto Company
TG1	<i>delta(lac-pro)</i> , <i>supE</i> , <i>thi-1</i> , <i>hsdD5/F'</i> (<i>traD36</i> , <i>proA</i> ⁺ <i>B</i> ⁺ , <i>lacI</i> ^q , <i>lacZdeltaM15</i>)	Amersham Corp., Arlington Heights, Illinois

DH5 α TM Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both *E. coli* strains TG1 and MON105 are rendered competent to take up DNA using a CaCl₂ method. Typically, 20 to 50 mL of cells are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto-yeast extract, 150 mM NaCl) to a density of approximately

1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, NY). The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl_2 solution (50 mM CaCl_2 , 10 mM Tris-Cl, pH7.4) and are held at 4°C for 30 minutes. The cells
5 are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl_2 solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4°C for 30-60 minutes. The samples are shifted to 42°C for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37°C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar)
10 containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants. The plates are incubated overnight at 37°C.

Colonies are picked and inoculated into LB plus appropriate antibiotic (100
15 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37°C while shaking.

Cloning and Expression

DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using
20 commercially available kits known to those skilled in the art. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, WI), the Qiagen QIAwell Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi or Mini kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000 x g), the plasmid DNA released
25 with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000 x g). The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted. After screening for the colonies with the plasmid of interest, the *E. coli* cells are inoculated into 50-100 ml of LB plus appropriate antibiotic for
30 overnight growth at 37°C in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into *E. coli*, mammalian cells, or other cell types.

Sequence confirmation

Purified plasmid DNA is resuspended in dH₂O and its concentration is determined by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the manufacturer's suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using ABI Model 373A and Model 377 automated DNA sequencers. Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI).

Mammalian Cell Transfection / Production of Conditioned Media

The BHK-21 cell line can be obtained from the ATCC (Rockville, MD). The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose), supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum (FBS). This formulation is designated growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (CalBiochem, San Diego, CA). The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 and pMON3633 and the IE175 promoter found in the plasmid pMON3360B (See Hippenmeyer et al., *Bio/Technology*, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 or IE175 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMON1118 (See Highkin et al., *Poultry Sci.*, 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid, pSV2-hph, is available from ATCC.

BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3 x 10⁵ cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM"™ (Gibco-BRL, Gaithersburg, MD) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid, pMON1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE"™ per dish.

The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours post-transfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the dish by trypsin-EDTA, diluted 1:10, and transferred to 100 mm tissue culture dishes containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of chimeras in E. coli

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37°C in M9 plus casamino acids medium with shaking in an air incubator Model G25 from New Brunswick Scientific (Edison, NJ). Growth is monitored at OD₆₀₀ until it reaches a value of 1.0 at which time nalidixic acid (10 mg/mL) in 0.1 N NaOH is added to a final concentration of 50 µg/mL. The cultures are then shaken at 37°C for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB). One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al., "Molecular Cloning: A Laboratory Manual", 1982). The culture is centrifuged (5000 x g) to pellet the cells.

Purification

Isolation of Inclusion Bodies

The cell pellet from a 330 mL *E. coli* culture is resuspended in 15 mL of sonication buffer (10 mM 2-amino-2-(hydroxymethyl) 1,3-propanediol hydrochloride (Tris-HCl), pH 8.0 + 1 mM ethylenediaminetetraacetic acid (EDTA). These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems-Ultrasonics, Inc., Farmingdale, New York). Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB). The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two

rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets

5 All steps are at 4°C. Angiostatin K1-4 inclusion bodies were dissolved in 6M urea, 5 mM DTT, 50 mM Bis-Tris Propane, pH 10.8 at 1.2 mg/ml. This solution was stirred for 2 hours and then 6-amino hexanoic acid (stock 1M) was added to achieve a 6 mM concentration, followed by addition of cystine (stock 0.2M, pH 10.5) to 1 mM. This was stirred for 5 minutes and then the K1-4 angiostatin was diluted to 0.2 mg/ml by addition of 75 mM Bis-Tris propane, pH 10.5. It was then stirred for 72 hours to complete the refolding of the protein.

10 *Purification*

Purification of angiostatin K1-4 was achieved using a Sepharose-Lys affinity column followed by Q-Sepharose chromatography. The sample was next dialyzed against 50 mM NaPO₄, pH 8.0 and then filtered through a 1 uM filter to clarify. This sample was loaded onto a Sepharose-Lys column equilibrated in 50 mM NaPO₄, pH 8.0. The load was at approximately 1.5 gm of K1-4 per ml of resin. After loading the column, it was washed with 1 column volume of equilibrating buffer and then K1-4 was eluted using a 10 column volume gradient from 0-8 mM 6-amino hexanoic acid in 50 mM NaPO₄, pH 8.0.

20 Fractions were analyzed by SDS-gel electrophoresis and/or RP-HPLC and pooled. This pool was made 40 mM Tris-Cl, and adjusted to pH 9.0. It was then dialyzed extensively vs. 40 mM Tris-Cl, pH 9.0 and applied to a Q-Sepharose HP column (~5 mgs protein/ml resin) equilibrated in the same buffer. K1-4 was then eluted using a NaCl gradient from 0-0.1M in the equilibrating buffer. Fractions were analyzed by RP-HPLC and/or SDS gel electrophoresis and pooled.

25 In some cases the folded proteins can be affinity-purified using affinity reagents such as monoclonal antibodies or receptor subunits attached to a suitable matrix. Purification can also be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC. These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 "Guide to Protein Purification" edited by Murray Deutscher, Academic Press, San Diego, California, 1990.

30 *Protein Characterization*

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

Biological Assays

Assay for Human Interferon-Induced Antiviral Activity

Antiviral activity induced by human interferon is measured spectrophotometrically as inhibition of the cytopathic effect that normally results from infection of Madin Darby bovine kidney cells, (ATCC CCL #22), with vesicular stomatitis virus (VSV) (ATCC VR-158) (Rubinstein et al., *J. Virol.* **37**(2): 755-758, 1981). VSV stocks are prepared on mouse L cells (L929) (ATCC CCL# 1). Samples of interferon are serially titrated in a 96-well plate format and incubated with 4×10^4 cells per well, 6 hours prior to addition of virus at a multiplicity of infection of 0.1 plaque forming units per cell. The cells are stained with crystal violet at 20-24 hours postinfection and staining is measured spectrophotometrically at 680 nm. The relative potencies of the samples are compared with Intron A, a recombinant interferon produced by Schering Plough and obtained by prescription.

Inhibitory effect on Proliferation of Daudi Cells

Human Burkitt's lymphoma Daudi cells (ATCC) are seeded at 2×10^4 cells /well into 96-well tissue culture plates and cells are cultured in the presence or absence of serial doses of rhIFN alpha 2b for 3 days. Cultures are pulsed with ^3H -thymidine for the last hour of the culture period, and the ^3H -thymidine uptake, counts per minute (cpm), measured on a Beta-plate reader. All samples are assayed in triplicate.

Endothelial cell proliferation assay

The endothelial cell proliferation assay was performed as described by Cao et al. (*J. Biol. Chem.* **271**: 29461-29467, 1996). Briefly, human dermal microvascular endothelial cells (HdMVEC, Clonetics) or bovine microvascular endothelial cells (BacEnd, Incell) were maintained in MCDB131 containing 5% heat-inactivated fetal bovine serum (FBS, Hyclone), antibiotics, 100 ug/ml heparin (Sigma) and 100 ug/ml endothelial mitogen (Biomedical Technologies). Confluent monolayers at passages 2-5 were dispersed in .05% trypsin and resuspended in

complete medium. Five hundred ul of complete media containing 1.25×10^4 cells were seeded into wells of a 24-well tissue culture plate coated with 0.1% gelatin (Sigma). The cells were incubated overnight at $37^\circ/5\% \text{ CO}_2$ at which time the media was replaced with 250 ul of media containing 5% FBS and various concentrations of inhibitors. After 30 minutes of incubation, 250 ul of media containing 1 ng/ml bFGF (R&D Systems) was added and the cells were incubated for an additional 72 hours, at which time they were trypsinized and counted with a Coulter counter.

Endothelial cell in vitro tube formation assay

The tube formation assay is performed as previous described (Gately et al., *Cancer Res.* 56:4887-4890, 1996). The effect of angiogenesis inhibitors can be tested in an in vitro angiogenesis assay; endothelial cell tube formation on matrix. Matrigel (Becton Dickson) was thawed on ice and diluted 1:1 with MCDB 131 medium supplemented with 2 mM L-glutamine, containing either buffer control or testing compounds. Aliquots of 0.5 ml of 1:1 diluted matrigel were plated into individual wells of 2-chambered Tissue-Tek polystyrene slides (Nunc) and allowed to polymerize at 37°C for at least 30 min. Primary bovine capillary endothelial cells derived from the bovine adrenal cortex (purchased from Incell) were cultured (as described for bovine endothelial cell proliferation). Following trypsinization, the cells were washed three times, then resuspended at 3.5×10^5 cells/ml in MCDB131 medium supplemented with L-glutamine and 1% fetal bovine serum containing either the same buffer control or testing compounds. The endothelial cells (0.5 ml at 3.5×10^5 cells /ml) were plated onto matrigel coated wells containing the same additives. After incubation for 16-24 hours at 37°C in a 5% CO_2 incubator, cultures were evaluated for tube formation (sprouting). Random fields of each experimental condition were photographed using a Nikon N6006 camera under a Nikon Diaphot microscope. The photographs were then quantitated by measuring the total length of the tubes. Tube formation can also be quantitated using image analysis software. Endothelial cell tube networks were fixed in 100% methanol at -20°C for 7-10 min, rinsed 4 times with phosphate buffered saline (PBS) and incubated overnight at 4°C with rabbit polyclonal anti-human Factor VIII-related antigen (von Willibrand factor, vWF) (Dako). The next day, the cells were stained with a secondary antibody, Cy3-conjugated goat anti-rabbit IgG F(ab')₂ specific (Jackson ImmunoResearch Laboratories). Tube formation was visualized using a Nikon microphot-FXA with a fluorescence filter linked to a computer containing image analysis software. Tube formation was measured as follows: Total area encompassed by endothelial cell tubes/Total endothelial cell

surface area.

Endothelial cell migration assay

The endothelial cell migration assay is performed essentially as previous described (Gately et al., *Cancer Res.* 56:4887-4890, 1996). To determine the ability of angiostatin to inhibit the migration of endothelial cells, migration assays were performed in a transwell chamber (Costar) containing 8 mm pore size polycarbonate membranes. The cells utilized in the assay were either human microvascular endothelial cells from Emory or bovine endothelial cells (kindly provided by Gately Northwestern University, Evanston, IL). The cells were starved overnight before use in MCDB131 + 0.1% BSA (human cells) or DMEM+0.1%BSA(bovine cells), harvested, and resuspended in the same media at 10^6 cells/ml. The lower side of the transwells were coated with 0.1% gelatin for 30 minutes at 37°C before addition of 2×10^5 cells to the upper chamber. The transwell was moved to a well containing the chemoattractant (bFGF or VEGF) in the lower chamber. Migration was allowed to occur overnight at 37°C. The membranes were then fixed and stained, and the number of cells that migrated to the lower side of the membrane counted in 3 high powered fields.

Micro-pocket assay to evaluate anti-angiogenic activity

The corneal micropocket assay has been developed to evaluate the anti-angiogenic activity of test compounds in mice. BALBc or C57BL strains of mice are anesthetized with avertin (tribromoethanol, 125 mpk, 0.3-4 ml/mouse, i.p., 25 ga needle). The eyes are topically anesthetized with 0.5% proparacaine. Only one eye is used. The eye is proptosed with a small forceps and under an operating microscope, a central, intrastromal linear keratotomy is performed with a #15 blade parallel to the insertion of the lateral rectus muscle. A modified cataract knife (1 x 20 mm) is then inserted to dissect a lamellar micropocket to within 1 mm of the temporal limbus. A single Hydron pellet containing either basic fibroblastic growth factor or vascular endothelial growth factor (bFGF or VEGF) is placed on the eye and pushed into the pocket with one arm of the forceps. The flap is self-sealing. Antibiotic ointment (Neobacimyx) is applied once to prevent infection and to decrease irritation of the irregular ocular surface.

Compounds are administered immediately post-operatively. They can be administered either orally, intraperitoneally, subcutaneously or intravenously, depending on bioavailability and potency of the compound. Dosing is from one to three times daily for oral compounds, one or two per day for i.p. or s.q., and once

per day via the tail vein for i.v. delivery. Volumes do not exceed 5 ml/kg orally, 10 ml/kg i.p. or s.q. or 2.5 ml/kg i.v. All injections are done with a 25 guage needle.

On post-operative day 5 or 6 the mice are anesthetized with avertin (125 mpk, i.p.), the eyes proptosed, and the degree of neovascularization assessed by determining the maximum vessel length, and the contiguous circumferential zone involved. Using the formula for the area of an ellipse, the neovascular area is measured. The animals receive a thoracotomy while still anesthetized, to assure euthanasia. Some of the eyes are removed for histology. If blood samples are required for compound blood levels, the mice are bled by cardiac puncture immediately following the corneal neovascularization assessment. This is done via a substernal approach with a 1 inch, 23 guage needle, and the animal is subsequently euthanized.

Animals are monitored daily following surgery. Topical proparacaine is used as necessary to relieve irritation of the affected eye. The maximum number of bleeds per rat is four, every third day, although typically only two are required, one at day 4 or 6 and one at completion.

Mouse models for anti-tumor activity

Several mouse models can be used to evaluate the anti-tumor activity of the chimeric proteins; either direct effects on the growth of the primary tumor or effects on metastasis. These can be divided into two broad classes: syngeneic models of mouse tumor in mice, such as the Lewis Lung Carcinoma (Sugiura and Stock, *Cancer Res.*, 15: 38-51, 1955; O'Reilly et al., *Cell (Cambridge, Mass)* **79**(2): 315-328, 1994) and xenograft models of human tumors in nude or severe combined immunodeficiency (SCID) mice. Examples of the human tumor xenografts include: the breast cancer cell lines, MDA-MB-435 (Price, *Breast Cancer Research and Treatment*, **39**: 93-102, 1996) and MDA-231 (Sasaki et al., *Can. Res.* **55**: 3551-3557, 1995), the human prostate carcinoma cell line, PC-3 (Pretlow et al, *Can. Res.* **51**: 3814-3817, 1991; Passaniti et al., *Int. J. Cancer*, **51**: 318-324, 1992) and the human melanoma line M21 (Felding-Habermann et al., *J. Clin. Invest.*, **89**: 2018-2022, 1992).

Examples

Example 1 Construction of plasmids encoding interferon alpha 2b

Construction of pMON30422

An interferon alpha 2b (IFN α -2b) gene was amplified from plasmid DNA from ATCC clone no. 67979 using the primer set, IF start (SEQ ID NO. 1) and IF stop (SEQ ID NO. 2).

5 Oligo Ifstart (SEQ ID NO:1)

GATCGACCAT GGCTTGTGAT CTGCCTCAAA CC 32

10 Oligo Ifstop (SEQ ID NO:2)

CGATCGAAGC TTATTATTCC TTA CTCTTA AACTTT 36

The primers were designed to include the appropriate restriction enzyme recognition sites which allow cloning of the gene into expression plasmids. Conditions for polymerase chain reaction (PCR) amplification were 35 cycles 92°C degree. denaturation for one minute, 40°C annealing for one minute and 72°C extension for one minute. A 100 ul reaction contained 100 pmol of each primer and one ug of template DNA (isolated by Qiagen Miniprep); and 1x PCR reaction buffer, 200 uM dNTPs and 0.6 unit Taq DNA polymerase (Boehringer Mannheim). The PCR product was digested with restriction endonucleases *Nco*I and *Hind*III and gel-purified. The vector pMON6875, encoding a *ptac* promoter, G10L ribosome binding site and P22 terminator, was digested with restriction endonucleases *Nco*I and *Hind*III. The digested PCR product and vector fragment were combined and ligated. A portion of the ligation reaction was used to transform *E. coli* strain MON208. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON30422.

Construction of pMON30426

To optimize expression of IFN α -2b in *E. coli*, a new gene with an optimized N-terminus was amplified from plasmid DNA from pMON30422 using the primer set, New IF-A (SEQ ID NO. 3) and IF stop (SEQ ID NO. 2).

30 Oligo IFstop (SEQ ID NO:2)

CGATCGAAGC TTATTATTCC TTA CTCTTA AACTTT 36

35

Oligo NewIF-A (SEQ ID NO:3)

GATCGACCAT GGCTTGTGAT CTGCCGCAAA CTCATAGCCT GGGTAGCCGT CGCACCCTGA 60

TGCTGCTGGC TCAGATGCGC CGTATCTCTC TTTTCTCCTG CTTGAAGGAC AGACA 115

40 The primers were designed to include the appropriate restriction enzyme

recognition sites which allow cloning of the gene into expression plasmids. Conditions for polymerase chain reaction (PCR) amplification were 35 cycles 92°C denaturation for one minute, 40°C annealing for one minute and 72°C extension for one minute. A 100 ul reaction contained 100 pmol of each primer and one ug of
5 template DNA; and 1x PCR reaction buffer, 200 uM dNTPs and 0.6 unit Taq DNA polymerase (Boehringer Mannheim). The PCR product was digested with restriction endonucleases NcoI and HindIII and gel-purified. Vector DNA encoding a *ptac* promoter, G10L ribosome binding site and P22 terminator, pMON6875, was digested with restriction endonucleases *NcoI* and *HindIII*. The digested PCR
10 product and vector fragment were combined and ligated. A portion of the ligation reaction was used to transform *E. coli* strain MON208. Transformed bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON30426. Both pMON30422 and pMON30426 encode the same peptide.

15 Example 2. Creation of human interferon alpha A/D chimeras

Construction of pMON20405

Plasmid, pMON30426, DNA was digested with the restriction enzymes *NcoI* and *HindIII* resulting in a 3207 bp vector fragment. Plasmid DNA from pMON30426 was digested with *NcoI* and *BglII* resulting in a 192 bp fragment.
20 The 192 bp fragment along with a 315 bp *BglII/HindIII* fragment that was assembled from synthetic oligonucleotides IFND1 (SEQ ID NO. 11), IFND2 (SEQ ID NO. 12), IFND3X (SEQ ID NO. 13), IFND4X (SEQ ID NO. 14), IFND5 (SEQ ID NO. 15), IFND6 (SEQ ID NO. 16), IFND7 (SEQ ID NO. 17), and IFND8 (SEQ ID NO. 18) was ligated to the vector fragment. A portion of the ligation reaction was
25 used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The genetic elements derived from plasmid pMON20405 are the pBR327 origin of replication, the *tac* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human
30 interferon (hIFN) alpha A/D hybrid, the P22 transcriptional terminator, and the streptomycin adenyltransferase gene.

Construction of pMON20407

Plasmid, pMON31236, DNA was digested with the restriction enzymes *NcoI* and *HindIII* resulting in a 3159 bp vector fragment. Plasmid DNA from
35 pMON20405 was digested with *NcoI* and *HindIII* resulting in a 507 bp fragment

that was ligated to the vector fragment. A portion of the ligation reaction was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. The genetic elements derived from plasmid pMON20407 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human interferon (hIFN) alpha A/D hybrid, the P22 transcriptional terminator, and the streptomycin adenyltransferase gene.

Construction of pMON20408

Plasmid DNA from pMON24646-A7 was mutagenized using the QuikChange Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA). The *NcoI* site that is present in the K3 domain of human angiostatin was removed by changing base 714 from A to T with synthetic oligonucleotides HPLGN-CD1 (SEQ ID NO. 19) AND HPLGN-CD2 (SEQ ID NO. 20). The genetic elements derived from plasmid pMON20408 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site joined to human angiostatin K1-3, the T7 transcriptional terminator and the streptomycin adenyltransferase gene.

Construction of pMON20409

An *NcoI* site was created at the 5' end of the K1-3 angiostatin DNA from plasmid pMON20408 by PCR using Stratagene's *Pfu* DNA polymerase and synthetic oligonucleotides HANGECSK1 (SEQ ID NO. 21) and ANGECSN3 (SEQ ID NO. 22). The PCR reaction was then treated with Taq polymerase (Boehringer Mannheim, Indianapolis, IN), extracted with phenol/chloroform and ligated into the pCR2.1 vector using the TA cloning kit from Invitrogen (San Diego, CA). A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain INVα F'. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert.

Construction of pMON20410

Construction of pMON20410, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON20410 encodes an IL-3 variant fused 5' to K1-3 angiostatin with the Gly Ser polypeptide linker. The 3551 bp *AflIII*, *HindIII* restriction fragment from pMON31250 was ligated with the 812bp *NcoI*, *HindIII* restriction fragment from

pMON20409. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and was analyzed by restriction analysis and sequenced to confirm the correct insert. The genetic elements derived from the intermediate plasmid pMON20410 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, an IL-3 variant joined to human angiostatin K1-3 with the GlySer polypeptide linker, the T7 transcription terminator and the streptomycin adenyltransferase gene.

10 *Construction of pMON20411*

The 3552 bp *Afl*II/*Hind*III restriction fragment from pMON31250 was ligated with the 507 bp *Nco*I/*Hind*III bp fragment from pMON20407. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and was analyzed by restriction analysis. The genetic elements derived from the intermediate plasmid pMON20411 are the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, IL-3 variant joined to human interferon alpha A/D hybrid with the GlySer polypeptide linker, the T7 transcription terminator and the streptomycin adenyltransferase gene.

Construction of pMON20412

Construction of pMON20412, which encodes K1-3 angiostatin fused 5' to the interferon alpha A/D hybrid. Plasmid DNA from pMON20411 was digested with the restriction enzymes *Nco*I and *Xma*I resulting in a 3695 bp vector fragment. Plasmid DNA from pMON20409 was digested with *Nco*I and *Mfe*I resulting in a 797 bp fragment that was ligated with an annealed pair of synthetic oligonucleotides K1K3INTU.REQ (SEQ ID NO. 23) and K1K3INTL.REQ (SEQ ID NO. 24) and the vector fragment. A portion of the ligation reaction was used to transform *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin plates. Plasmid DNA was isolated from a colony grown in LB broth and was analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenyltransferase gene.

35 *Construction of pMON20420*

Construction of pMON20420, which encodes interferon alpha A/D hybrid fused 5' to the K1-3 angiostatin with the Gly Ser polypeptide linker. Plasmid DNA from pMON20410 is digested with the restriction enzymes *NcoI* and *XmaI* resulting in a 4000 bp vector fragment. Plasmid DNA from pMON20407 is digested with *NcoI* and *AccI* resulting in a 467 bp fragment that is ligated with an annealed pair of synthetic oligonucleotides IFADINTU.REQ (SEQ ID NO. 25) and IFADINTL.REQ (SEQ ID NO. 26) and the vector fragment. A portion of the ligation reaction is used to transform *E. coli* K-12 strain JM101. Transformant bacteria are selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth and was analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

15 *Construction of pMON20421*

Construction of pMON20421, which encodes K1 angiostatin fused 5' to the interferon alpha A/D hybrid with the Gly Ser polypeptide linker. The 3480 bp *AflII/HindIII* restriction fragment from pMON31251 is ligated with the 507 bp *NcoI, HindIII* bp fragment from pMON20407. A portion of the ligation reaction is used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria are selected on spectinomycin-containing plates. Plasmid DNA was isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenylyltransferase gene.

25 *Construction of pMON20422*

Construction of pMON20422, which encodes interferon alpha A/D hybrid fused 5' to the K1 angiostatin with the Gly Ser polypeptide linker. Plasmid DNA from pMON31252 is digested with the restriction enzymes *NcoI* and *XmaI* resulting in a 3391 bp vector fragment. Plasmid DNA from pMON20407 is digested with *NcoI* and *AccI* resulting in a 467 bp fragment that is ligated with an annealed pair of synthetic oligonucleotides IFADINTU.REQ (SEQ ID NO. 25) and IFADINTL.REQ (SEQ ID NO. 26) and the vector fragment. A portion of the ligation reaction is used to transform competent *E. coli* K-12 strain JM101. Transformed bacteria were selected on spectinomycin plates. Plasmid DNA was

isolated from a colony grown in LB broth and is analyzed by restriction analysis, and sequenced to confirm the correct insert. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin
5 adenyltransferase gene.

Construction of pMON31250

pMON31250, an intermediate plasmid, was used for the construction of plasmids containing DNA sequences encoding multi-functional proteins. It encodes an IL-3 variant fused 5' to the GlySer polypeptide linker, and contains
10 *AflIII* and *HindIII* cloning sites at the 3' end of the polypeptide linker. The 3159 bp *NcoI*, *HindIII* restriction fragment from pMON31236 was ligated with the 413 bp *NcoI*, *HindIII* fragment from pMON13180. A portion of the ligation reaction was used to transform competent *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was
15 isolated from a colony grown in LB broth containing spectinomycin and analyzed by restriction analysis. Other genetic elements include the pBR327 origin of replication, the *recA* promoter, the gene 10 leader (g10-L) ribosome binding site, the T7 transcription terminator and the streptomycin adenyltransferase gene.

Example 3. Creation of angiostatin / interferon alpha 2b chimeras

20 *Construction of pMON20413*

Construction of plasmid pMON20413, which encodes K1 angiostatin fused 5' to the interferon alpha 2b sequence. Plasmid pMON31251 was digested with restriction enzymes *AflIII* and *HindIII*, resulting in a 3477 bp *AflIII/HindIII* vector fragment. Plasmid pMON30426 which encodes interferon alpha 2b, was digested
25 with *NcoI* and *HindIII*, resulting in release of a 507 bp fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform *E. coli* strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

30 *Construction of pMON20414*

Construction of pMON20414, which encodes interferon alpha 2b fused 5' to the K1 angiostatin sequence. Plasmid pMON31252 was digested with the restriction enzymes *NcoI* and *XmaI*, resulting in a 3447 bp *NcoI/XmaI* vector

Construction of pMON31251, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON31251 encodes K1 angiostatin fused 5' to the GlySer linker sequence, and contains *Afl*III and *Hind*III cloning sites at the 3' end of the insert DNA. Plasmid

pMON31250 was digested with restriction enzymes *Nco*I and *Xma*I, resulting in a 3208 bp *Nco*I, *Xma*I vector fragment. Plasmid pMON24649 which encodes the K1 domain of angiostatin was digested with *Nco*I and *Ear*I, resulting in a 255 bp *Nco*I/*Ear*I fragment. The 255 bp *Nco*I/*Ear*I fragment from pMON24649 was
 5 ligated for 3 h with the following pair of annealed complementary oligonucleotides:

Oligo #K1intU (SEQ ID NO. 8)

GTGTGAAGAG GAATACGTAG AGGGCGGTGG AGGCTCC

37

Oligo #K1intL (SEQ ID NO. 7)

10

CCGGGGAGCC TCCACCGCCC TCTACGTATT CCTCTTCA

38

The assembled oligonucleotides create *Ear*I and *Xma*I restriction ends and removes the termination codons from the angiostatin K1 sequence. This fuses the angiostatin K1 sequence to the GlySer linker sequence (SEQ ID NO. 79). After 3 h
 15 ligation, the mixture was added to the 3208 bp *Nco*I, *Xma*I pMON31250 DNA fragment and the ligation continued for 15 h. This was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

20 *Construction of pMON31252*

Construction of pMON31252, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins. pMON31252 encodes K1 angiostatin fused 3' to the GlySer coding sequence (SEQ ID NO. 79). Plasmid pMON31250 was digested with restriction enzymes *Afl*III and *Hind*III, resulting in a 275 bp *Afl*III, *Hind*III vector fragment. Plasmid
 25 pMON24649 was digested with the restriction enzymes *Nco*I and *Hind*III, resulting in a 3552 bp *Nco*I/*Hind*III fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates.
 30 Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Construction of pMON31259

Construction of pMON31259, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding fusion proteins.
 35 pMON31259 encodes domains K1 through K3 of angiostatin fused 5' to the GlySer

linker sequence (SEQ ID NO. 79), and contains *Afl*III and *Hind*III cloning sites at the 3' end of the insert DNA. Plasmid pMON31250 was digested with restriction enzymes *Nco*I and *Xma*I, resulting in a 3208 bp *Nco*I, *Xma*I vector fragment. Plasmid pMON20409 was digested with *Nco*I and *Mfe*I, resulting in release of a
 5 798 bp *Nco*I/*Mfe*I fragment. The 798 bp *Nco*I/*Mfe*I fragment from pMON20409 was ligated for 3 h with the following pair of annealed complementary oligonucleotides:

Oligo #K1K3intU (SEQ ID NO. 10)

AATTGGCTTA CGTAGAGGGC GGTGGAGGCT CC 32

Oligo #K1K3intL (SEQ ID NO. 9)

10 CCGGGGAGCC TCCACCGCCC TCTACGTAAG CC 32

The assembled oligonucleotides create *Mfe*I and *Xma*I sites and remove the termination codons from the K1-K3 angiostatin sequence. This fuses the angiostatin K1-K3 sequence to the GlySer linker sequence. After 3 h ligation, the mixture was added to the 3208 bp *Nco*I, *Xma*I pMON31250 DNA fragment and the
 15 ligation continued for 15 h. This was used to transform *E. coli* K-12 strain JM101. Transformant bacteria were selected on spectinomycin-containing plates. Plasmid DNA was isolated from colonies and sequenced to confirm the correct insert.

Example 4. Construction of plasmids encoding Kringle domains of angiostatin

20 *Construction of pMON24624*

A cDNA encoding the heavy chain of human plasminogen (pMON24624, SEQ ID NO: 37) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers hplgn-s1 (SEQ ID NO: 104) and hplgn-n1 (SEQ ID NO: 105), and using cDNA synthesized from human liver mRNA as a template. This
 25 cDNA encodes the signal peptide, N-terminal peptide and the five Kringle domains of human plasminogen. The resulting DNA was cleaved with the restriction endonuclease *Bam*HI and ligated into the mammalian expression vector pMON3360B, which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B. Plasmid DNA was isolated from
 30 ampicillin-resistant bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24625

A cDNA encoding the first four Kringle domains (K1-4) of human

plasminogen (24625.seq, SEQ ID NO: 38) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s1 (SEQ ID NO: 106) and angpcr-n1 (SEQ ID NO: 107). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B. Plasmid DNA was isolated from ampicillin-resistant bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24625 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24626

A cDNA encoding the first three Kringle domains (K1-3) of human plasminogen (24626.seq, SEQ ID NO: 39) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s1 (SEQ ID NO: 106) and angpcr-n2 (SEQ ID NO: 108). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24626 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24627

A cDNA encoding Kringle domains two through four (K2-4) of human plasminogen (24627.seq, SEQ ID NO: 40) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s2 (SEQ ID NO: 109) and angpcr-n1 (SEQ ID NO: 107). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease

cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24627 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24628

A cDNA encoding Kringle domains two and three (K2-3) of human plasminogen (24628.seq, SEQ ID NO: 41) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angpcr-s2 (SEQ ID NO: 109) and angpcr-n2 (SEQ ID NO: 108). The resulting DNA was cleaved with the restriction endonucleases *NcoI* and *HindIII* and ligated into the mammalian expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The resulting protein expressed from pMON24628 includes the human interleukin 3 signal peptide (encoded by vector sequences) fused at the amino terminus of the plasminogen Kringle domains in such a way as to insure secretion of the protein product.

Construction of pMON24630

Plasmid pMON24625 was cleaved with restriction endonuclease *BamHI*. The 1161 bp cDNA released by such digestion encodes the first four Kringle (K1-4) domains of human plasminogen fused to the human interleukin 3 signal peptide (24625.seq, SEQ ID NO: 38). The baculovirus expression vector pFastBac1 was cleaved with *BamHI* and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24631

Plasmid pMON24626 was cleaved with restriction endonuclease *BamHI*. The 873 bp cDNA released by such digestion encodes the first three Kringle domains (K1-3) of human plasminogen fused to the human interleukin 3 signal

peptide (24626.seq, SEQ ID NO: 39). The baculovirus expression vector pFastBac1 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to
5 ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24632

Plasmid pMON24625 was cleaved with restriction endonuclease *Bam*HI.
10 The 1161 bp cDNA released by such digestion encodes the first four Kringle (K1-4) domains of human plasminogen fused to the human interleukin 3 signal peptide (24625.seq, SEQ ID NO: 38). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A
15 portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24633

Plasmid pMON24626 was cleaved with restriction endonuclease *Bam*HI.
20 The 873 bp cDNA released by such digestion encodes the first three Kringle domains (K1-3) of human plasminogen fused to the human interleukin 3 signal peptide (24626.seq, SEQ ID NO: 41). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to
25 prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24636

Plasmid pMON24627 was cleaved with restriction endonuclease *Bam*HI.
The 909 bp cDNA released by such digestion encodes Kringle domains two through four (K2-4) of human plasminogen fused to the human interleukin 3 signal peptide (24627.seq, SEQ ID NO: 40). The baculovirus expression vector pFastBac1 was

cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and
5 analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity.

Construction of pMON24637

Plasmid pMON24628 was cleaved with restriction endonuclease *Bam*HI. The 621 bp cDNA released by such digestion encodes Kringle domains two and
10 three (K2-3) of human plasminogen fused to the human interleukin 3 signal peptide (24628.seq, SEQ ID NO: 41). The baculovirus expression vector pFastBac1 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to
15 ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity.

Construction of pMON24638

Plasmid pMON24627 was cleaved with restriction endonuclease *Bam*HI. The 909 bp cDNA released by such digestion encodes Kringle domains two through
20 four (K2-4) of human plasminogen fused to the human interleukin 3 signal peptide (24627.seq, SEQ ID NO: 40). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to prevent recircularization. The cleaved vector and the cDNA were ligated together. A
25 portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24639

Plasmid pMON24628 was cleaved with restriction endonuclease *Bam*HI. The 621 bp cDNA released by such digestion encodes Kringle domains two and
30 three (K2-3) of human plasminogen fused to the human interleukin 3 signal peptide (24628.seq, SEQ ID NO: 41). The *Pichia pastoris* expression vector pPIC3 was cleaved with *Bam*HI and digested with Shrimp Alkaline Phosphatase to

prevent recircularization. The cleaved vector and the cDNA were ligated together. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24642

A cDNA encoding the first four Kringle domains (K1-4*) of human plasminogen (24642.seq, SEQ ID NO: 42) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angeg-s1 (SEQ ID NO: 103) and angeg-n1 (SEQ ID NO: 100). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had been cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (angee-s1) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA. The protein encoded by pMON24642 is a somewhat longer version of the K1-4 encoded by the cDNA in pMON24643.

Construction of pMON24643

A cDNA encoding the first four Kringle domains (K1-4) of human plasminogen (24643.seq, SEQ ID NO: 43) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers angeg-s2 (SEQ ID NO: 102) and angeg-n2 (SEQ ID NO: 99). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had been cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (angee-s2) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B

host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

5 *Construction of pMON24644*

 A cDNA encoding domains two and three (K2-3) of human plasminogen (24644.seq, SEQ ID NO: 44) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s3 (SEQ ID NO: 101) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases
10 *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s3 SEQ ID NO: 101) contained degeneracies at the third positions of the first few codons. This resulted in a
15 population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease
20 cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24645

 A cDNA encoding Kringle domains two through four (K2-4) of human plasminogen (24645.seq, SEQ ID NO: 45) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s3 (SEQ ID NO: 101) and
25 anged-n2 (SEQ ID NO: 99). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s3) contained
30 degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA
35 was isolated from bacterial colonies and analyzed by restriction endonuclease

cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24646

5 A cDNA encoding the first three Kringle domains (K1-3) of human plasminogen (24646.seq, SEQ ID NO: 46) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers anged-s2 (SEQ ID NO: 102) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases *Afl*III and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. 10 In order to optimize expression in *E. coli*, the 5' PCR primer (anged-s2) contained degeneracies at the third positions of the first few codons. This resulted in a population of plasmids, each encoding the same protein, but with different silent mutations in some of the first few codons. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. 15 Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24648

20 A cDNA encoding the first Kringle domain (K1) of human plasminogen (24648.seq, SEQ ID NO: 47) was synthesized by polymerase chain reaction (PCR) using the oligonucleotide primers hanged-sk1 (SEQ ID NO: 110) and anged-n3 (SEQ ID NO: 98). The resulting DNA was cleaved with the restriction endonucleases *Nco*I and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. 25 In order to optimize expression in *E. coli*, the 5' PCR primer (hanged-sk1) contained the same nucleotide sequence found in the K1-3 cDNA in pMON24646. Plasmid DNA was isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. 30 Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24649

A cDNA encoding the first kringle domain of human angiostatin was

synthesized by polymerase chain reaction using the primers Hang-ec-sk1.seq and ang-ec-n4.seq using pMON24646-A7 as template. The resulting DNA was cleaved with the restriction endonucleases *Nco*I and *Hind*III and ligated into the *E. coli* expression vector pMON5723 which had cleaved with *Nco*I and *Hind*III. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to spectinomycin resistance. Plasmids were isolated from the DH10B host strain and used to transform *E. coli* strain MON105 to spectinomycin resistance. Individual isolates were screened for protein expression. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24650

pMON24649 was cleaved with *Nco*I and *Hind*III releasing the cDNA encoding the first Kringle (K1) of human plasminogen (24649.seq, SEQ ID NO: 112). The K1 cDNA was ligated into the mammalian cell expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Construction of pMON24652

pMON20412 was cleaved with *Nco*I and *Hind*III releasing the cDNA encoding the first three Kringles of human plasminogen fused to the IFN alpha A/D cDNA. The cDNA was ligated into the mammalian cell expression vector pMON3633 which had been similarly cleaved. A portion of the ligation reaction was used to transform *E. coli* strain DH10B to ampicillin resistance. Plasmid DNA was isolated from bacterial colonies and analyzed by restriction endonuclease cleavage and DNA sequencing to confirm the identity of the cDNA.

Example 5. Purification of angiostatin / interferon alpha 2b chimeras

Plasmid pMON24652, encoding an angiostatin K1-3/interferon A/D chimeric protein, was transfected into BHK/VP16 cells and stable cell lines selected as described above in the materials and methods (Hippenmeyer, P. and Highkin, M. Bio/Technology 11: 1037-1041, 1993). Thirty-six clones were isolated and six clones selected for testing in roller bottles. The concentration of the chimeras were determined by ELISA using a commercially-available human IFN-alpha ELISA kit (Biosource #KHC4012). Clone 15 produced the most chimera, 14.4 ug/ml, while the

other five clones produced much less (clones 8, 14, 29, 32, and 36 each produced 1.17, 2.22, 0.04, 0.20, and 1.12 ug/ml, respectively).

A 50 ml lysine sepharose column was pre-equilibrated at 4°C with 50 mM sodium phosphate, pH 7.4. About 500 ml of a 12X concentrate of conditioned serum-free media (SF-BHK) was loaded onto the column at 4°C with a flow rate of about 2.5 ml/min. The column was washed with 50 mM sodium phosphate, pH 7.4, followed by a wash containing 500 mM NaCl in 50 mM sodium phosphate, pH 7.4, to remove non-specific binding proteins. The column was then equilibrated back to a low salt environment with two column volumes of 50 mM sodium phosphate, pH 7.4. The desired chimera was eluted by washing the column with 200 mM epsilon-amino caproic acid in 50 mM sodium phosphate, pH 7.4. Approximately 10.5 ml fractions were collected and the elution monitored by UV absorption. Fractions 4-6 absorbed significant UV and were combined. These fractions were dialyzed three times at 4°C against 4 liters of 50 mM sodium phosphate, pH 7.4, and sterile filtered. Analytical lysine sepharose chromatography yielded a final concentration of about 0.6 mg/ml.

SDS-PAGE analysis of the purified sample on reducing and non-reducing gels indicated that the chimera migrated at a position close to its expected size. Electron spray mass spectrometry indicated a molecular weight of about 51,556 daltons, indicating that the material isolated from BHK cells is partially glycosylated.

The purified chimera was assayed for endothelial cell migration, in triplicate, as described in the materials and methods. The results are shown in the table below:

25 HMEC migration

Sample	Cells/HPF
Media	14.33 ± 3.84
VEGF	190.00 ± 16.46
VEGF + Intron A (500 U/ul)	111.11 ± 25.47
VEGF + IFN A/D (500 U/ul)	131.78 ± 19.90
VEGF + IFN A/D (5000 U/ul)	44.89 ± 18.48
VEGF + Angiostatin K1-K3/IFN A/D (0.3 ug/ul)	73.22 ± 8.80
VEGF + Angiostatin K1-K3/IFN A/D (30 ug/ul)	35.11 ± 18.51
VEGF + Angiostatin K1-K3 prepared from <i>E. coli</i> (30 ug/ul)	130.56 ± 7.04

Interferon alpha A/D from a commercial source (Genzyme) and the angiostatin/IFN A/D chimera were also tested twice in a Daudi cell proliferation assay using a series of 3-fold dilutions, each beginning at a concentration of 1 nM. The interferon A/D and the angiostatin/interferon A/D chimera had similar inhibition profiles (Figure 5).

All references, patents, or applications cited herein are incorporated by reference in their entirety.

Tables

Plasmids

Plasmid	SEQ ID NO.	Marker	Description	Source
pFastBac1		Amp, Gent	Baculovirus donor plasmid containing multiple cloning site downstream of an AcNPV polyhedrin promoter within a mini-Tn7 transposable element.	Life Technologies, Inc.
pPIC3		Amp, HIS3	<i>Pichia pastoris</i> expression vector	Invitrogen Company
pMON3360 B			Mammalian expression vector for use in BHK/VP16 cells	Hippenmeyer, P. and Highkin, M. Bio/Technology 11: 1037-1041, 1993
pMON3633			Mammalian expression vector for use in BHK/VP16 cells	This reference
pMON5723		Spec	Generic Spec-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site	
pMON6875		Spec	Generic Spec-resistant <i>E. coli</i> expression vector containing the <i>E. coli recA1</i> promoter and G10L ribosome binding site	

WO 99/16889

- 50 -

PCT/US98/20464

pMON13180	Amp	Intermediate plasmid containing an IL-3 variant fused to a Gly-Ser polypeptide linker (SEQ ID NO: 79). Contains an <i>NcoI</i> site at the 5' end of the IL-3 variant coding sequences and <i>AflIII</i> and <i>HindIII</i> cloning sites at the 3' end of the linker region.	WO 97/12985
pMON20405	Spec	3207 bp <i>NcoI/HindIII</i> frag from pMON30426 + 192 bp frag from pMON30426 (A portion of IFN alpha) + 315 bp frag from 8 synthetic oligos with <i>BglIII/HindIII</i> ends (D portion of IFN alpha). Creates IFN alpha A/D hybrid.	This reference
pMON20407	Spec	3159 bp <i>NcoI/HindIII</i> frag from pMON31236 + 507 bp frag from pMON20405 (IFN alpha A/D hybrid)	This reference
pMON20408	Spec	Removed <i>NcoI</i> site in K3 region of angiostatin K1-K3 in pMON24646-A7	This reference
pMON20409	Spec	Created <i>NcoI</i> site at the 5' end of K1-K3 angiostatin	This reference
pMON20410	Spec	3551 bp <i>AflIII, HindIII</i> fragment from pMON31250 + 812 bp frag from pMON20409 (creates chimera IL-3 variant K1-K3 angiostatin)	This reference

WO 99/16889

- 51 -

PCT/US98/20464

pMON20411		Spec	3551 bp <i>Afl</i> III, <i>Hind</i> III frag from pMON31250 + 507 bp frag from pMON20407 (creates chimera IL-3 variant/IFN A/D hybrid)	This reference
pMON20412		Spec	3695 bp <i>Nco</i> I/ <i>Xma</i> I frag from pMON20411 + 797 bp <i>Nco</i> I/ <i>Mfe</i> I frag from pMON20409 + 1 pair of synthetic oligonucleotides with <i>Mfe</i> I/ <i>Xma</i> I ends (creates K1- K3/IFN A/D hybrid chimera)	This reference
pMON20413	#35	Spec	3447 bp <i>Afl</i> III/ <i>Hind</i> III fragment from pMON31251 + 507 bp <i>Nco</i> I/ <i>Hind</i> III fragment of pMON30426 (creates K1- GlySer-IFN a2b hybrid)	This reference
pMON20414	#31	Spec	3447 <i>Nco</i> I/ <i>Xma</i> I from pMON312b2 + 447 bp <i>Nco</i> I/ <i>Bsp</i> HI frag from pMON30426 + synthetic oligos with <i>Bsp</i> HI/ <i>Xma</i> I ends (creates IFN a2b-GlySer-K1 hybrid)	This reference
pMON20416	#33	Spec	4017 bp <i>Afl</i> III/ <i>Hind</i> III vector from pMON31259 + 507 bp <i>Nco</i> I/ <i>Hind</i> III fragment from pMON30426 (creates K1-K3- IFN a2b hybrid)	This reference

WO 99/16889

- 52 -

PCT/US98/20464

pMON20420	#30	Spec	4000 bp <i>NcoI/XmaI</i> frag from pMON20410 + 467 bp <i>NcoI</i> , <i>AccI</i> frag from pMON20407 + 1 pair of synthetic oligonucleotides with <i>AccI/XmaI</i> ends (creates IFN A/D hybrid/K1-K3 angiostatin chimera	This reference
pMON20421	#34	Spec	3480 bp <i>AflIII/HindIII</i> frag from pMON31251 + 507 bp <i>NcoI/HindIII</i> frag from pMON20407 creates a chimera of K1/IFN A/D hybrid	This reference
pMON20422	#29	Spec	3491 bp <i>NcoI/XmaI</i> frag from pMON31252 + 467 <i>NcoI/AccI</i> bp frag from pMON20407 + 1 pair of synthetic oligonucleotides with <i>AccI/XmaI</i> ends (creates IFN A/D hybrid/K1 angiostatin chimera)	This reference
pMON24624	#37	Amp	Human plasminogen heavy chain including the native plasminogen signal sequence, N-terminal peptide and kringles 1-5. <i>BamHI</i> fragment in pMON3360B. (Amino acids - 19-537 of plasminogen, nucleotides 55-1752)	This reference

WO 99/16889

- 53 -

PCT/US98/20464

pMON24625	#38	Amp	Human angiostatin(S) including kringles 1-4 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 79-440 of plasminogen, nucleotides 346- 1431)	This reference
pMON24626	#39	Amp	K1-3 fragment of human angiostatin(S) including kringles 1-3 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON 3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 79-344 of plasminogen, nucleotides 346- 1143)	This reference
pMON24627	#40	Amp	K2-4 fragment of human angiostatin (S) including kringles 2-4 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 163-440 of plasminogen, nucleotides 598- 1431)	This reference

WO 99/16889

- 54 -

PCT/US98/20464

pMON24628	#41	Amp	K2-3 fragment of human angiostatin(S) including kringles 2-3 of hPlgn. <i>AflIII/HindIII</i> fragment in pMON3633. Seq file includes hIL3 signal sequence contributed by the vector. (Amino acids 163-344 of plasminogen, nucleotides 598-1143)	This reference
pMON24630		Amp	K1-4 cDNA (<i>Bam</i> HI fragment) from pMON24625 cloned into baculovirus transfer vector pFastBac1.	This reference
pMON24631		Amp	K1-3 cDNA (<i>Bam</i> HI fragment) from pMON24626 cloned into baculovirus transfer vector pFastBac1.	This reference
pMON24632		Amp, HIS3	K1-4 cDNA (<i>Bam</i> HI fragment) from pMON24625 cloned into <i>Pichia pastoris</i> expression vector pPIC3.	This reference
pMON24633		Amp, HIS3	K1-3 cDNA (<i>Bam</i> HI fragment) from pMON24626 cloned into <i>Pichia pastoris</i> expression vector pPIC3.	This reference
pMON24634		Kan, Gent	K1-4 cDNA (<i>Bam</i> HI fragment) from pMON24625 transposed into the bacmid bMON14272.	This reference
pMON24635		Kan, Gent	K1-3 cDNA (<i>Bam</i> HI fragment) from pMON24626 transposed into the bacmid bMON14272.	This reference

WO 99/16889

- 55 -

PCT/US98/20464

pMON24636	Amp	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24627 cloned into	
		baculovirus transfer vector	
		pFastBac1.	
pMON24637	Amp	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24628 cloned into	
		baculovirus transfer vector	
		pFastBac1.	
pMON24638	Amp, HIS3	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24627 cloned into	
		<i>Pichia pastoris</i> expression	
		vector pPIC3.	
pMON24639	Amp, HIS3	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24628 cloned into	
		<i>Pichia pastoris</i> expression	
		vector pPIC3.	
pMON24640	Kan, Gent	K2-4 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24627 transposed	
		into the bacmid bMON14272.	
pMON24641	Kan, Gent	K2-3 cDNA (<i>Bam</i> HI fragment)	This reference
		from pMON24628 transposed	
		into the bacmid bMON14272.	
pMON24642	#42 spec	Human angiostatin(E).	This reference
		<i>Afl</i> III/ <i>Hind</i> III fragment in	
		pMON5723. The 5' end has	
		been mutagenized for increased	
		expression. (Amino acids 74-	
		470 of plasminogen,	
		nucleotides 331-1464)	

WO 99/16889

- 56 -

PCT/US98/20464

pMON24643	#43	spec	Human angiostatin(S) (K1-4) <i>AflIII/HindIII</i> fragment in pMON5723. (Amino acids 79-440 of plasminogen, nucleotides 346-1431)	This reference
pMON24644	#44	spec	K2-3 fragment of human angiostatin(S). <i>AflIII/HindIII</i> fragment in pMON5723. (Amino acids 163-344 of plasminogen, nucleotides 598-1143)	This reference
pMON24645	#45	spec	K2-4 fragment of human angiostatin(S). <i>AflIII/HindIII</i> fragment in pMON5723. (Amino acids 163-440 of plasminogen, nucleotides 598-1431)	This reference
pMON24646	#46	spec	K1-3 fragment of human angiostatin(S). <i>AflIII/HindIII</i> fragment in pMON5723. (Amino acids 79-344 of plasminogen, nucleotides 346-1143)	This reference
pMON24648	#47	spec	K1 fragment of human angiostatin(S). <i>NcoI/HindIII</i> fragment in pMON5723. (Amino acids 79-184 of plasminogen, nucleotides 7 (24644A7.seq) -607)	This reference

WO 99/16889

- 57 -

PCT/US98/20464

pMON24649	#112	spec	K1 fragment of human angiotatin(S). <i>NcoI/HindIII</i> fragment in pMON5723. (Amino acids 79-184 of plasminogen, nucleotides 1-269 of pMON24646-A7.seq)	This reference
pMON24650	#48	Amp	K1 fragment of human angiotatin(S). <i>NcoI/HindIII</i> fragment in pMON3633. (Amino acids 79-184 of plasminogen)	This reference
pMON24652	#49	Amp	K1-3 fragment of human angiotatin/IFN A/D (<i>NcoI/HindIII</i> fragment from pMON20412) in pMON3633.	This reference
pMON30422	#27	spec	Interferon alpha 2b	This reference
pMON30426	#28	spec	Interferon alpha 2b with optimized N-terminal codons	This reference
pMON31236		Spec	Similar to pMON5723 with the exception of the <i>NcoI/HindIII</i> insert	This reference
pMON31250		Spec	3159 bp <i>NcoI/HindIII</i> frag from pMON31236 + 413 bp <i>NcoI/HindIII</i> fragment from pMON13180 (creates an intermediate for making fusion proteins in the new spec vector)	This reference

WO 99/16889

- 58 -

PCT/US98/20464

pMON31251	Spec	3208 bp <i>NcoI/XmaI</i> fragment of pMON31250 + 255 <i>NcoI/EarI</i> fragment of pMON24649 + synthetic oligos with <i>EarI/XmaI</i> ends (creates K1-Gly-Ser hybrid intermediate plasmid)	This reference
pMON31252	Spec	3552 <i>AflIII/HindIII</i> fragment from pMON31250 + 275 bp <i>NcoI/HindIII</i> fragment from pMON24649 (creates Gly-Ser-angiotensin K1 hybrid)	This reference
pMON31259	Spec	3208 bp <i>NcoI/XmaI</i> fragment of pMON31250 + 798 bp <i>NcoI/MfeI</i> fragment of pMON20409 + synthetic oligos with <i>MfeI/XmaI</i> ends (creates K1-K3-Gly-Ser hybrid intermediate plasmid)	This reference

SEQ ID Correlation table

SEQ ID NO.	SEQ ID Name
1	Oligo Ifstart
2	Oligo Ifstop
3	Oligo NewIF-A
4	Oligo IFADINTL
5	Oligo IFNAINTL
6	Oligo IFNAINTU
7	Oligo K1NTL
8	Oligo K1NTU
9	Oligo K1K3INTL
10	Oligo K1K3INTU
11	Oligo INFd1
12	Oligo IFND2
13	Oligo IFND3X
14	Oligo IFND4X
15	Oligo IFND5
16	Oligo IFND6
17	Oligo IFND7
18	Oligo IFND8
19	Oligo HPLGN-CD1
20	Oligo HPLGN-CD2
21	Oligo HANGECSK1
22	Oligo ANGECN3
23	Oligo K1K3INTU
24	Oligo K1K3INTL
25	Oligo IFADINTU
26	Oligo IFADINTL
27	30422.seq
28	30426.seq
29	IFN adk1.seq (20422)
30	IFN adk1_3.seq (20420)
31	IFN argk1.seq (20414)
32	IFN argk1_3.seq ()
33	K1_3IFN arg.seq (20416)
34	K1IFN ad.seq (20421)
35	K1IFN arg.seq (20413)
36	K1-K3IFN ad.seq (20412)
37	pMON24624.seq
38	pMON24625_bam.seq
39	pMON24626_bam.seq
40	pMON24627.seq
41	pMON24628.seq
42	pMON24642_B5.seq
43	pMON24643-C10.seq
44	pMON24644-E7.seq
45	pMON24645-G3.seq

46 pMON24646-A7.seq
47 pMON24648_E7.seq
48 pMON24650.seq
49 pMON24652.seq
50 huendostatin.seq
51 human_plgn.seq
52 huvasculostatin.seq
53 30422.pep
54 30426.pep
55 IFNadk1.pep
56 IFNadk1_3.pep
57 IFNargk1.pep
58 IFNargk1_3.pep
59 K1_K3IFNarg.pep
60 K1IFNad.pep
61 K1IFNarg.pep
62 K1-K3IFNaD.pep
63 pMON24624.pep
64 pMON24625.pep
65 pMON24626.pep
66 pMON24627.pep
67 pMON24628.pep
68 pMON24642.pep
69 pMON24643.pep
70 pMON24644.pep
71 pMON24645.pep
72 pMON24646.pep
73 pMON24648.pep
74 pMON24650.pep
75 pMON24652.pep
76 huendostatin.pep
77 hplasminogen.pep
78 Huvasculostatin.pep
79 Peptide linker, Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly
Gly Ser Gly Gly Gly Ser Asn
80 Peptide linker, Gly Gly Gly Ser
81 Peptide linker, Gly Gly Gly Ser Gly Gly Gly Ser
82 Peptide linker, Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
Ser
83 Peptide linker, Ser Gly Gly Ser Gly Gly Ser
84 Peptide linker, Glu Phe Gly Asn Met Ala
85 Peptide linker, Glu Phe Gly Gly Asn Met Ala
6 Peptide linker, Glu Phe Gly Gly Asn Gly Gly Asn Met Ala
87 Peptide linker, Gly Gly Ser Asp Met Ala Gly
88 Peptide linker G3s
89 Peptide linker G4s
90 Peptide linker G5s
91 Peptide linker AGS

WO 99/16889

- 61 -

PCT/US98/20464

92	Peptide linker G6S
93	Peptide linker M13
94	Peptide linker Hinge1
95	Peptide linker Hinge2
96	Oligo hang sk1
97	Oligo hangedec_ec_sk1
98	Oligo angedec n3
99	Oligo angedec n2
100	Oligo angedec n1
101	Oligo angedec s3
102	Oligo angedec s2
103	Oligo angedec s1
104	Oligo Hplgn_S1
105	Oligo Hplgn_N1
106	Oligo angpccr_s1
107	Oligo angpccr_n1
108	Oligo angpccr_n2
109	Oligo angpccr_s2
110	Oligo Hang_Ec_Sk1
111	Oligo angedec_N4
112	24649.seq
113	24649.pep

WO 99/16889

- 1 -

PCT/US98/20464

SEQLIST.TXT

SEQUENCE LISTING

5 <110> Bolanowski, Mark A.
 Caparon, Maire H.
 Casperson, Gerald F.
 Gregory, Susan A.
 Klein, Barbara K.
 McKearn, John P.

10 <120> Multi-functional Proteins

15 <130> C-3026

<150> 60/060,609
 <151> 1997-10-02

20 <160> 113

<170> FastSEQ for Windows Version 3.0
 <210> 1
 <211> 32
 <212> DNA
 <213> human

<400> 1
 gatcgaccat ggcttgtgat ctgcctcaaa cc 32

30 <210> 2
 <211> 36
 <212> DNA
 <213> human

35 <400> 2
 cgatcgaagc ttattattcc ttactttctta aacttt 36

40 <210> 3
 <211> 115
 <212> DNA
 <213> human

<400> 3
 45 gatcgaccat ggcttgtgat ctgccgcaaa ctcatagcct gggtagccgt cgcaccctga 60
 tgctgctggc tcagatgcgc cgtatctctc ttttctcctg cttgaaggac agaca 115

50 <210> 4
 <211> 61
 <212> DNA
 <213> human

WO 99/16889

- 2 -

PCT/US98/20464

<400> 4
 ccggggagcc tccaccgccc tctacgtatt ccttacgacg cagacgttct tgcaggttgg 60
 t 61

5
 <210> 5
 <211> 79
 <212> DNA
 <213> human

10
 <400> 5
 ccggggagcc tccaccgccc tctacgtatt ccttacttct taaactttct tgcaagtttg 60
 ttgacaaaga aaaagatct 79

15
 <210> 6
 <211> 79
 <212> DNA
 <213> human

20
 <400> 6
 catgagatct ttttctttgt caacaaactt gcaagaaagt ttaagaagta aggaatacgt 60
 agagggcggt ggaggctcc 79

25
 <210> 7
 <211> 38
 <212> DNA
 <213> human

30
 <400> 7
 ccggggagcc tccaccgccc tctacgtatt cctcttca 38

35
 <210> 8
 <211> 37
 <212> DNA
 <213> human

40
 <400> 8
 gtgtgaagag gaatacgtag agggcggtgg aggctcc 37

45
 <210> 9
 <211> 32
 <212> DNA
 <213> human

50
 <400> 9
 ccggggagcc tccaccgccc tctacgtaag cc 32

<210> 10
 <211> 32
 <212> DNA
 <213> human

<400> 10
 aattggctta cgtagagggc ggtggaggct cc 32

WO 99/16889

- 3 -

PCT/US98/20464

<210> 11
 <211> 80
 <212> DNA
 <213> human

5

<400> 11
 gatcttcaac ctgtttacca ccaaagattc ttctgctgct tgggatgagg acctgctgga 60
 caaattctgc accgaactgt 80

10

<210> 12
 <211> 84
 <212> DNA
 <213> human

15

<400> 12
 ctgctggtac agttcgggtgc agaatttgct cagcagggtcc tcatcccaag cagcagaaga 60
 atctttggtg gtaaacaggt tgaa 84

20

<210> 13
 <211> 80
 <212> DNA
 <213> human

25

<400> 13
 accagcagct gaacgacctc gaagcctgtg tgatgcagga ggagcgtgtg ggtgaaactc 60
 cgctgatgaa cgtggactcc 80

30

<210> 14
 <211> 80
 <212> DNA
 <213> human

35

<400> 14
 gccaggatgg agtccacgtt catcagcgga gtttcaccca cacgctcctc ctgcatcaca 60
 caggcttcga ggtcgttcag 80

40

<210> 15
 <211> 80
 <212> DNA
 <213> human

45

<400> 15
 atcctggctg tgaagaaata ctccgctcgt atcactctgt atctgactga gaagaaatac 60
 agcccgtgtg cttgggaggt 80

50

<210> 16
 <211> 80
 <212> DNA
 <213> human

<400> 16
 cacgaacaac ctcccaagca cacgggctgt atttcttctc agtcagatac agagtgatac 60
 gacggaagta tttcttcaca 80

WO 99/16889

- 4 -

PCT/US98/20464

5
 <210> 17
 <211> 75
 <212> DNA
 <213> human
 <400> 17
tggttcgtgct gaaatcatgc gttccctgtc tctgtctacc aacctgcaag aacgtctgcg 60
tcgtaaggaa taata 75

10
 <210> 18
 <211> 71
 <212> DNA
 <213> human

15
 <400> 18
agcttattat tccttacgac gcagacgttc ttgcaggttg gtagacagag acaggggaacg 60
catgatttca g 71

20
 <210> 19
 <211> 29
 <212> DNA
 <213> human

25
 <400> 19
ggaaaaaggg ccccttggtg ccatacaac 29

30
 <210> 20
 <211> 29
 <212> DNA
 <213> human

35
 <400> 20
gttgtatggc accaaggggc cctttttcc 29

40
 <210> 21
 <211> 30
 <212> DNA
 <213> human

45
 <400> 21
catgccatgg cagtttatct ttcagagtgt 30

50
 <210> 22
 <211> 34
 <212> DNA
 <213> human

55
 <400> 22
gatcaagctt ttattaagcc aattgttccg tgga 34

60
 <210> 23
 <211> 32
 <212> DNA
 <213> human

WO 99/16889

- 5 -

PCT/US98/20464

	<400> 23	
	aattggctta cgtagagggc ggtggaggct cc	32
5	<210> 24	
	<211> 32	
	<212> DNA	
	<213> human	
10	<400> 24	
	ccggggagcc tccaccgcc tctacgtaag cc	32
	<210> 25	
	<211> 59	
15	<212> DNA	
	<213> human	
	<400> 25	
20	ctaccaacct gcaagaacgt ctgcgtcgta aggaatacgt agagggcggg ggaggtcc	59
	<210> 26	
	<211> 61	
	<212> DNA	
	<213> human	
25	<400> 26	
	ccggggagcc tccaccgcc tctacgtatt ccttacgacg cagacgttct tgcaggttg	60
	t	61
30	<210> 27	
	<211> 507	
	<212> DNA	
	<213> human	
35	<400> 27	
	atggcttgtg atctgcctca aaccacacgc ctgggtagca ggaggacctt gatgctcctg	60
	gcacagatga ggagaatctc tcttttctcc tgcttgaagg acagacatga ctttggattt	120
	ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccatccctgt cctccatgag	180
	atgatccagc agatcttcaa tctcttcagc acaaaggact catctgctgc ttgggatgag	240
40	accctcctag acaaattcta cactgaactc taccagcagc tgaatgacct ggaagcctgt	300
	gtgatacagg ggggtgggggt gacagagact cccctgatga aggaggactc cattctggct	360
	gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcccttgt	420
	gcctgggagg ttgtcagagc agaaatcatg agatcttttt ctttgtcaac aaacttgcaa	480
	gaaagttaa gaagtaagga ataataa	507
45	<210> 28	
	<211> 507	
	<212> DNA	
	<213> human	
50	<400> 28	
	atggcttgtg atctgccgca aactcatagc ctgggtagcc gtcgcacct gatgctgctg	60
	gtcagatgc gccgtatctc tcttttctcc tgcttgaagg acagacatga ctttggattt	120
	ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccatccctgt cctccatgag	180

WO 99/16889

- 6 -

PCT/US98/20464

5	atgatccagc agatcttcaa tctcttcagc acaaaggact catctgctgc ttgggatgag	240
	accctcctag acaaattcta cactgaactc taccagcagc tgaatgacct ggaagcctgt	300
	gtgatacagg ggggtgggggt gacagagact cccctgatga aggaggactc cattctggct	360
	gtgaggaaat acttccaaag aatcactctc tatctgaaag agaagaaata cagcccttgt	420
	gcctgggagg ttgtcagagc agaaatcatg agatcttttt ctttgtcaac aaacttgcaa	480
	gaaagttaa gaagtaagga ataataa	507
10	<210> 29	
	<211> 822	
	<212> DNA	
	<213> human	
15	<400> 29	
	atggcttgtg atctgccgca aactcatagc ctgggtagcc gtcgcaccct gatgctgctg	60
	gtcagatgc gccgtatctc tcttttctcc tgcttgaagg acagacatga ctttggattt	120
	ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccatccctgt cctccatgag	180
	atgatccagc agatcttcaa cctgtttacc accaaagatt cttctgctgc ttgggatgag	240
20	gacctgctgg acaaattctg caccgaactg taccagcagc tgaacgacct cgaagcctgt	300
	gtgatgcagg aggagcgtgt gggtgaaact ccgctgatga acgtggactc catcctggct	360
	gtgaagaaat acttccgtcg tatcactctg tatctgactg agaagaaata cagcccgtgt	420
	gcttgggagg ttgttcgtgc tgaaatcatg cgttccctgt ctctgtctac caacctgcaa	480
	gaacgtctgc gtcgtaagga atacgtagag ggcggtggag gctccccggg tggtggttct	540
25	ggcgggcggct ccaacatggc agtttatctt tcagagtgtg agactgggaa tggaaagaat	600
	tacagaggga cgatgtccaa aacaaaaaat ggcatcacct gtcaaaaatg gagttccact	660
	tctccccaca gacctagatt ctcacctgct acacaccctt cagagggact ggaggagaac	720
	tactgcagga atccagacaa cgatccgcag gggccctggg gctatactac tgatccagaa	780
	aagagatatg actactgcga cattcttgag tgtgaagagg aa	822
30	<210> 30	
	<211> 1359	
	<212> DNA	
	<213> human	
35	<400> 30	
	atggcttgtg atctgccgca aactcatagc ctgggtagcc gtcgcaccct gatgctgctg	60
	gtcagatgc gccgtatctc tcttttctcc tgcttgaagg acagacatga ctttggattt	120
	ccccaggagg agtttggcaa ccagttccaa aaggctgaaa ccatccctgt cctccatgag	180
	atgatccagc agatcttcaa cctgtttacc accaaagatt cttctgctgc ttgggatgag	240
40	gacctgctgg acaaattctg caccgaactg taccagcagc tgaacgacct cgaagcctgt	300
	gtgatgcagg aggagcgtgt gggtgaaact ccgctgatga acgtggactc catcctggct	360
	gtgaagaaat acttccgtcg tatcactctg tatctgactg agaagaaata cagcccgtgt	420
	gcttgggagg ttgttcgtgc tgaaatcatg cgttccctgt ctctgtctac caacctgcaa	480
	gaacgtctgc gtcgtaagga atacgtagag ggcggtggag gctccccggg tggtggttct	540
45	ggcgggcggct ccaacatggc agtttatctt tcagagtgtg agactgggaa tggaaagaat	600
	tacagaggga cgatgtccaa aacaaaaaat ggcatcacct gtcaaaaatg gagttccact	660
	tctccccaca gacctagatt ctcacctgct acacaccctt cagagggact ggaggagaac	720
	tactgcagga atccagacaa cgatccgcag gggccctggg gctatactac tgatccagaa	780
	aagagatatg actactgcga cattcttgag tgtgaagagg aatgtatgca ttgcagtgga	840
50	gaaaactatg acggcaaaat ttccaagacc atgtctggac tggaaatgcca ggccctggac	900
	tctcagagcc cacacgtca tggatacatt ctttccaaat ttccaaacaa gaacctgaag	960
	aagaattact gtcgtaaccc cgatagggag ctgcggcctt ggtgtttcac caccgacccc	1020
	aacaagcgtt gggaactttg tgacatcccc cgctgcacaa cacctccacc atcttctggt	1080
	cccacctacc agtgtctgaa gggaacaggt gaaaactatc gcgggaatgt ggctgttacc	1140
	gtgtccgggc acacctgtca gcaactggagt gcacagaccc ctcacacaca taacaggaca	1200

WO 99/16889

- 7 -

PCT/US98/20464

ccagaaaact	tcccctgcaa	aaatttggat	gaaaactact	gccgcaatcc	tgacggaaaa	1260
agggccctt	ggtgccatac	aaccaacagc	caagtgcggt	gggagtactg	taagataccg	1320
tcctgtgact	cctccccagt	atccacggaa	caattggct			1359

5 <210> 31
 <211> 822
 <212> DNA
 <213> human

10 <400> 31

atggcttgtg	atctgccgca	aactcatagc	ctgggtagcc	gtcgcaccct	gatgctgctg	60
gctcagatgc	gccgtatctc	tcttttctcc	tgcttgaagg	acagacatga	ctttggattt	120
ccccaggagg	agtttggcaa	ccagttccaa	aaggctgaaa	ccatccctgt	cctccatgag	180
atgatccagc	agatcttcaa	tctcttcagc	acaaaggact	catctgctgc	ttgggatgag	240
accctcctag	acaaattcta	cactgaactc	taccagcagc	tgaatgacct	ggaagcctgt	300
gtgatacagg	gggtgggggt	gacagagact	cccctgatga	aggaggactc	cattctggct	360
gtgaggaaat	acttccaaag	aatcactctc	tatctgaaag	agaagaaata	cagcccttgt	420
gcctgggagg	ttgtcagagc	agaaatcatg	agatcttttt	ctttgtcaac	aaacttgcaa	480
gaaagttaa	gaagtaagga	atacgtagag	ggcggtaggag	gctccccggg	tggtggttct	540
ggcggcggt	ccaacatggc	agtttatctt	tcagagtgtg	agactgggaa	tggaaagaat	600
tacagaggga	cgatgtccaa	aacaaaaaat	ggcatcacct	gtcaaaaatg	gagttccact	660
tctccccaca	gacctagatt	ctcacctgct	acacaccct	cagagggact	ggaggagAAC	720
tactgcagga	atccagacaa	cgatccgcag	gggccttggg	gctatactac	tgatccagaa	780
aagagatatg	actactgcga	cattcttgag	tgtgaagagg	aa		822

25 <210> 32
 <211> 1359
 <212> DNA
 <213> human

30 <400> 32

atggcttgtg	atctgccgca	aactcatagc	ctgggtagcc	gtcgcaccct	gatgctgctg	60
gctcagatgc	gccgtatctc	tcttttctcc	tgcttgaagg	acagacatga	ctttggattt	120
ccccaggagg	agtttggcaa	ccagttccaa	aaggctgaaa	ccatccctgt	cctccatgag	180
atgatccagc	agatcttcaa	tctcttcagc	acaaaggact	catctgctgc	ttgggatgag	240
accctcctag	acaaattcta	cactgaactc	taccagcagc	tgaatgacct	ggaagcctgt	300
gtgatacagg	gggtgggggt	gacagagact	cccctgatga	aggaggactc	cattctggct	360
gtgaggaaat	acttccaaag	aatcactctc	tatctgaaag	agaagaaata	cagcccttgt	420
gcctgggagg	ttgtcagagc	agaaatcatg	agatcttttt	ctttgtcaac	aaacttgcaa	480
gaaagttaa	gaagtaagga	atacgtagag	ggcggtaggag	gctccccggg	tggtggttct	540
ggcggcggt	ccaacatggc	agtttatctt	tcagagtgtg	agactgggaa	tggaaagaat	600
tacagaggga	cgatgtccaa	aacaaaaaat	ggcatcacct	gtcaaaaatg	gagttccact	660
tctccccaca	gacctagatt	ctcacctgct	acacaccct	cagagggact	ggaggagAAC	720
tactgcagga	atccagacaa	cgatccgcag	gggccttggg	gctatactac	tgatccagaa	780
aagagatatg	actactgcga	cattcttgag	tgtgaagagg	aatgtatgca	ttgcagtggg	840
gaaaactatg	acggcaaaat	ttccaagacc	atgtctggac	tggaatgcca	ggcctgggac	900
tctcagagcc	cacacgctca	tgatacatt	ccttccaaat	ttccaaacaa	gaacctgaag	960
aagaattact	gtcgtaaccc	cgatagggag	ctgcggcctt	ggtgtttcac	caccgacccc	1020
aacaagcgt	gggaactttg	tgacatcccc	cgtgcacaaa	cacctccacc	atcttctggt	1080
cccacctacc	agtgtctgaa	gggaacaggt	gaaaactatc	gcgggaatgt	ggctgttacc	1140
gtgtccgggc	acacctgtca	gcactggagt	gcacagaccc	ctcacacaca	taacaggaca	1200
ccagaaaact	tcccctgcaa	aaatttggat	gaaaactact	gccgcaatcc	tgacggaaaa	1260
agggccctt	ggtgccatac	aaccaacagc	caagtgcggt	gggagtactg	taagataccg	1320
tcctgtgact	cctccccagt	atccacggaa	caattggct			1359

WO 99/16889

- 8 -

PCT/US98/20464

5 <210> 33
 <211> 1359
 <212> DNA
 <213> human

<400> 33
 atggcagttt atctttcaga gtgtaagact gggaatggaa agaattacag agggacgatg 60
 tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct 120
 10 agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca 180
 gacaacgata cgcaggggcc ctggtgctat actactgata cagaaaagag atatgactac 240
 tgcgacattc ttgagtgtga agaggaatgt atgcattgca gtggagaaaa ctatgacggc 300
 aaaatttcca agaccatgtc tggactggaa tggcaggcct gggactctca gagcccacac 360
 gctcatggat acattccttc caaatttcca aacaagaacc tgaagaagaa ttactgtcgt 420
 15 aaccccgata gggagctgcg gccttgggtg ttaccaccg accccaacaa gcgctgggaa 480
 ctttgtgaca tcccccgctg cacaacacct ccaccatctt ctggtccac ctaccagtgt 540
 ctgaagggaa caggtgaaaa ctatcgaggg aatgtggctg ttaccgtgtc cgggcacacc 600
 tgtcagcact ggagtgcaca gacccctcac acacataaca ggacaccaga aaacttcccc 660
 tgcaaaaatt tggatgaaaa ctactgccgc aatcctgacg gaaaaagggc cccttgggtgc 720
 20 catacaacca acagccaagt gcggtgggag tactgtaaga taccgtcctg tgactcctcc 780
 ccagtatcca cggaacaatt ggcttacgta gagggcggtg gaggtcccc ggggtgggtg 840
 tctggcggcg gctccaacat ggcttgtgat ctgccgcaa ctcatagcct gggtagccgt 900
 cgcacctga tgctgctggc tcagatgcgc cgtatctctc ttttctcctg cttgaaggac 960
 agacatgact ttggatttcc ccaggaggag tttggcaacc agttccaaaa ggctgaaacc 1020
 25 atccctgtcc tccatgagat gatccagcag atcttcaatc tcttcagcac aaaggactca 1080
 tctgctgctt gggatgagac cctcctagac aaattctaca ctgaactcta ccagcagctg 1140
 aatgacctgg aagcctgtgt gatacagggg gtgggggtga cagagactcc cctgatgaag 1200
 gaggactcca ttctggctgt gaggaatac ttccaaagaa tcactctcta tctgaaagag 1260
 aagaaataca gcccttgtgc ctgggaggtt gtcagagcag aaatcatgag atctttttct 1320
 30 ttgtcaacaa acttgcaaga aagtttaaga agtaaggaa 1359

35 <210> 34
 <211> 822
 <212> DNA
 <213> human

<400> 34
 atggcagttt atctttcaga gtgtaagact gggaatggaa agaattacag agggacgatg 60
 tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct 120
 40 agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca 180
 gacaacgata cgcaggggcc ctggtgctat actactgata cagaaaagag atatgactac 240
 tgcgacattc ttgagtgtga agaggaatac gtagagggcg gtggaggctc cccgggtggt 300
 ggttctggcg gcggtccaa catggcttgt gatctgccgc aaactcatag cctgggtagc 360
 cgtegcaccc tgatgctgct ggctcagatg cgccttatct ctcttttctc ctgcttgaag 420
 45 gacagacatg actttggatt tccccaggag gagtttggca accagttcca aaaggctgaa 480
 accatccctg tcttccatga gatgatccag cagatcttca acctgtttac caccaaagat 540
 tcttctgctg cttgggatga ggacctgctg gacaaattct gcaccgaact gtaccagcag 600
 ctgaacgacc tcgaagcctg tgtgatgcag gaggagcgtg tgggtgaaac tccgctgatg 660
 aacgtggact ccatcctggc tgtgaagaaa tacttccgct gtatcactct gtatctgact 720
 50 gagaagaaat acagcccgtg tgcttgggag gttgttcgtg ctgaaatcat gcgttccctg 780
 tctctgtcta ccaacctgca agaacgtctg cgtcgtaagg aa 822

<210> 35
 <211> 822

WO 99/16889

- 9 -

PCT/US98/20464

<212> DNA

<213> human

<400> 35

5	atggcagttt atctttcaga gtgtaagact gggaatggaa agaattacag agggacgatg	60
	tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct	120
	agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca	180
	gacaacgata cgcagggggc ctggtgctat actactgata cagaaaagag atatgactac	240
	tgcgacattc ttgagtgtga agaggaatac gtagagggcg gtggaggctc cccgggtggt	300
10	ggttctggcg gcggctccaa catggcttgt gatctgccgc aaactcatag cctgggtagc	360
	cgctgcaccc tgatgctgct ggctcagatg cgccgtatct ctcttttctc ctgcttgaag	420
	gacagacatg actttggatt tccccaggag gagtttggca accagttcca aaaggctgaa	480
	accatccctg tcctccatga gatgatccag cagatcttca atctcttcag cacaaaggac	540
	tcattctgctg cttgggatga gacctccta gacaaattct aactgaact ctaccagcag	600
15	ctgaatgacc tggaagcctg tgtgatacag ggggtggggg tgacagagac tccctgatg	660
	aaggaggact ccattctggc tgtgaggaaa tacttccaaa gaatcactct ctatctgaaa	720
	gagaagaaat acagcccttg tgctggggag gttgtcagag cagaaatcat gagatctttt	780
	tctttgtcaa caaacttgca agaaagttta agaagtaagg aa	822

20

<210> 36

<211> 1359

<212> DNA

<213> human

25

<400> 36

	atggcagttt atctttcaga gtgtaagact gggaatggaa agaattacag agggacgatg	60
	tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct	120
	agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca	180
	gacaacgata cgcagggggc ctggtgctat actactgata cagaaaagag atatgactac	240
30	tgcgacattc ttgagtgtga agaggaatgt atgcattgca gtggagaaaa ctatgacggc	300
	aaaatttcca agaccatgtc tggactggaa tgccaggcct gggactctca gagcccacac	360
	gctcatggat acattccttc caaatttcca aacaagaacc tgaagaagaa ttactgtcgt	420
	aaccccgata gggagctgag gccttgggtg ttcaccaccg accccaacaa gcgctgggaa	480
	ctttgtgaca tccccgctg cacaacacct ccaccatctt ctgggtccac ctaccagtgt	540
35	ctgaagggaa cagggtgaaaa ctatcgcggg aatgtggctg ttaccgtgtc cgggcacacc	600
	tgtcagcact ggagtgacaa gaccttcac acacataaca ggacaccaga aaacttcccc	660
	tgcaaaaatt tggatgaaaa ctactgccgc aatcctgacg gaaaaagggc cccttgggtg	720
	catacaacca acagccaagt gcggtgggag tactgtaaga taccgtcctg tgactcctcc	780
	ccagtatcca cggaacaatt ggcttacgta gagggcggtg gaggtcctcc ggggtgggtg	840
40	tctggcgggc gctccaacat ggcttgtgat ctgccgcaa ctcatagcct gggtagccgt	900
	cgcacctga tgctgctggc tcagatgcgc cgtatctctc ttttctcctg cttgaaggac	960
	agacatgact ttggatttcc ccaggaggag tttggcaacc agttccaaaa ggctgaaacc	1020
	atccctgtcc tccatgagat gatccagcag atcttcaacc tgtttaccac caaagattct	1080
	tctgctgctt gggatgagga cctgctggac aaattctgca ccgaactgta ccagcagctg	1140
45	aacgacctcg aagcctgtgt gatgcaggag gagcgtgtgg gtgaaactcc gctgatgaac	1200
	gtggactcca tcctggctgt gaagaaatac ttccgtcgta tcactctgta tctgactgag	1260
	aagaaataca gcccggtgtg ttggggaggt gtctgtgctg aaatcatgag ttccctgtct	1320
	ctgtctacca acctgcaaga acgtctgcgt cgtaaggaa	1359

50

<210> 37

<211> 1719

<212> DNA

<213> human

WO 99/16889

- 10 -

PCT/US98/20464

<400> 37

	ggatccgcca	ccatggaaca	taaggaagtg	gttcttctac	ttctttttatt	tctgaaatca	60
	ggtcaaggag	agcctctgga	tgactatgtg	aatacccagg	gggcttcact	gttcagtgtc	120
	actaagaagc	agctgggagc	aggaagtata	gaagaatgtg	cagcaaaatg	tgaggaggac	180
5	gaagaattca	cctgcagggc	attccaatat	cacagtaaag	agcaacaatg	tgtgataatg	240
	gctgaaaaca	ggaagtcctc	cataatcatt	aggatgagag	atgtagtttt	atttgaaaag	300
	aaagtgtatc	tctcagagtg	caagactggg	aatggaaaga	attacagagg	gacgatgtcc	360
	aaaacaaaaa	atggcatcac	ctgtcaaaaa	tggagttcca	cttctcccca	cagacctaga	420
	ttctcacctg	ctacacaccc	ctcagaggga	ctggaggaga	actactgcag	gaatccagac	480
10	aacgatccgc	aggggccttg	gtgctatact	actgatccag	aaaagagata	tgactactgc	540
	gacattcttg	agtgtgaaga	ggaatgtatg	cattgcagtg	gagaaaacta	tgacggcaaa	600
	atttccaaga	ccatgtctgg	actggaatgc	caggcctggg	actctcagag	cccacacgct	660
	catggataca	ttccttccaa	atttccaaac	aagaacctga	agaagaatta	ctgtcgtaac	720
	cccgataggg	agctgcggcc	ttggtgtttc	accaccgacc	ccaacaagcg	ctgggaactt	780
15	tgtgacatcc	cccgctgcac	aacacctcca	ccatcttctg	gtcccaccta	ccagtgtctg	840
	aagggaaacag	gtgaaaacta	tcgcgggaat	gtggctgtta	ccgtgtccgg	gcacacctgt	900
	cagcactgga	gtgcacagac	ccctcacaca	cataacagga	caccagaaaa	cttcccctgc	960
	aaaaatttgg	atgaaaacta	ctgccgcaat	cctgacggaa	aaagggcccc	atggtgccat	1020
	acaaccaaca	gccaagtgcg	gtggggagtac	tgtaagatac	cgtcctgtga	ctcctcccca	1080
20	gtatccacgg	aacagttggc	tcccacagca	ccacctgagc	taaccctgt	ggtecaggac	1140
	tgctaccatg	gtgatggaca	gagctaccga	ggcacatcct	ccaccaccac	cacaggaaag	1200
	aagtgtcagt	cttggtcac	tatgacacca	caccggcacc	agaagacccc	agaaaactac	1260
	ccaaatgctg	gcctgacaat	gaactactgc	aggaatccag	atgccgataa	aggcccctgg	1320
	tgtttttacca	cagaccccag	cgtcaggtgg	gagtactgca	acctgaaaaa	atgctcagga	1380
25	acagaagcga	gtgttgtagc	acctccgcct	gttgtcctgc	ttccagatgt	agagactcct	1440
	tccgaagaag	actgtatgtt	tgggaatggg	aaaggatacc	gaggcaagag	ggcgaccact	1500
	gttactggga	cgccatgcca	ggactgggct	gcccaggagc	cccatagaca	cagcattttc	1560
	actccagaga	caaatccacg	ggcggtctg	gaaaaaaatt	actgccgtaa	ccctgatggt	1620
	gatgtaggtg	gtccctggtg	ctacacgaca	aatccaagaa	aactttacga	ctactgtgat	1680
30	gtccctcagt	gtgcggcccc	ttcatttgat	taaggatcc			1719

<210> 38

<211> 1167

<212> DNA

35 <213> human

<400> 38

	ggatccacca	tgagccgcct	gcccgtcctg	ctcctgtctc	aactcctggg	ccgccccgcc	60
	atgtctgtgt	atctctcaga	gtgcaagact	gggaatggaa	agaattacag	agggacgatg	120
40	tccaaaacaa	aaaatggcat	cacctgtcaa	aaatggagtt	ccacttctcc	ccacagacct	180
	agattctcac	ctgctacaca	cccctcagag	ggactggagg	agaactactg	caggaatcca	240
	gacaacgatc	cgcagggggc	ctggtgctat	actactgac	cagaaaagag	atatgactac	300
	tgcgacattc	ttgagtgtga	agaggaatgt	atgcattgca	gtggagaaaa	ctatgacggc	360
	aaaattttcca	agaccatgtc	tggactggaa	tgccaggcct	gggactctca	gagcccacac	420
45	gctcatggat	acattccttc	caaattttcca	aacaagaacc	tgaagaagaa	ttactgtcgt	480
	aaccccgata	gggagctgcg	gccttggtgt	ttcaccaccg	accccaacaa	gcgctgggaa	540
	ctttgtgaca	tccccgcgtg	cacaacacct	ccaccatctt	ctgggtcccac	ctaccagtgt	600
	ctgaagggaa	caggtgaaaa	ctatcgcggg	aatgtggctg	ttaccgtgtc	cgggcacacc	660
	tgtcagcact	ggagtgcaca	gaccctcac	acacataaca	ggacaccaga	aaacttcccc	720
50	tgcaaaaatt	tggatgaaaa	ctactgccgc	aatcctgacg	gaaaaagggc	cccatggtgc	780
	catacaacca	acagccaagt	gcggtgggag	tactgtgaaga	taccgtcctg	tgactcctcc	840
	ccagtatcca	cggaacagtt	ggctcccaca	gcaccacctg	agctaacccc	tgtggtccag	900
	gactgctacc	atggtgatgg	acagagctac	cgaggcacat	cctccaccac	caccacagga	960
	aagaagtgtc	agtcttggtc	atctatgaca	ccacaccggc	accagaagac	cccagaaaac	1020

WO 99/16889

- 11 -

PCT/US98/20464

tacccaaatg	ctggcctgac	aatgaactac	tgcaggaatc	cagatgccga	taaaggcccc	1080
tgggtgtttta	ccacagaccc	cagcgtcagg	tgggagtact	gcaacctgaa	aaaatgctca	1140
ggaacagaag	cgtgaaagct	tggatcc				1167

5 <210> 39
 <211> 879
 <212> DNA
 <213> human

10	<400> 39	
	ggatccacca	tgagccgect gcccgtcctg ctctgtctcc aactcctggt ccgccccgcc 60
	atgtctgtgt	atctctcaga gtgcaagact gggaatggaa agaattacag agggacgatg 120
	tccaaaacaa	aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct 180
	agattctcac	ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca 240
15	gacaacgatc	cgcagggggc ctggtgctat actactgatc cagaaaagag atatgactac 300
	tgcgacattc	ttgagtgtga agaggaatgt atgcattgca gtggagaaaa ctatgacggc 360
	aaaatttcca	agaccatgtc tggactggaa tgccaggcct gggactctca gagccccacac 420
	gctcatggat	acattccttc caaatttcca aacaagaacc tgaagaagaa ttactgtcgt 480
	aaccccgata	gggagctgcg gccttggtgt ttcaccaccg accccaacaa gcgctgggaa 540
20	ctttgtgaca	tccccgctg cacaacacct ccaccatctt ctgggtcccac ctaccagtgt 600
	ctgaagggaa	caggtgaaaa ctatcgcggg aatgtggctg ttaccgtgtc cgggcacacc 660
	tgtcagcact	ggagtgcaca gaccctcac acacataaca ggacaccaga aaacttcccc 720
	tgcaaaaatt	tggatgaaaa ctactgccgc aatcctgacg gaaaaagggc cccatgggtgc 780
	catacaacca	acagccaagt gcggtgggag tactgtgaaga taccgtcctg tgactcctcc 840
25	ccagtatcca	cggaacagtt ggcttgaaag cttggatcc 879

 <210> 40
 <211> 915
 <212> DNA
 <213> human

30	<400> 40	
	ggatccacca	tgagccgect gcccgtcctg ctctgtctcc aactcctggt ccgccccgcc 60
	atgtctgaag	aggaatgtat gcattgcagt ggagaaaact atgacggcaa aatttccaag 120
35	accatgtctg	gactggaatg ccaggcctgg gactctcaga gcccacacgc tcatggatac 180
	attccttcca	aatttccaaa caagaacctg aagaagaatt actgtcgtaa ccccgatagg 240
	gagctgcggc	cttgggtgttt caccaccgac cccaacaagc gctgggaact ttgtgacatc 300
	ccccgctgca	caacacctcc accatcttct ggtcccacct accagtgtct gaagggaaca 360
	ggtgaaaact	atcgcgggaa tgtggctgtt accgtgtccg ggcacacctg tcagcactgg 420
40	agtgcacaga	ccctcacac acataacagg acaccagaaa acttccccctg caaaaatttg 480
	gatgaaaact	actgccgcaa tcctgacgga aaaagggccc catggtgcca tacaaccaac 540
	agccaagtgc	ggtgggagta ctgtaagata ccgtcctgtg actcctcccc agtatccacg 600
	gaacagttgg	ctcccacagc accacctgag ctaacccttg tgggccagga ctgctaccat 660
	ggtgatggac	agagctaccg aggcacatcc tccaccacca ccacaggaaa gaagtgtcag 720
45	tcttggtcat	ctatgacacc acaccggcac cagaagacct cagaaaacta cccaaatgct 780
	ggcctgacaa	tgaactactg caggaatcca gatgccgata aaggccccctg gtgttttacc 840
	acagacccca	gcgtcagggt ggagtactgc aacctgaaaa aatgctcagg aacagaagcg 900
	tgaaagcttg	gatcc 915

50 <210> 41
 <211> 627
 <212> DNA
 <213> human

WO 99/16889

- 12 -

PCT/US98/20464

	<400> 41	
	ggatccacca tgagccgcct gcccgctctg ctctgtctcc aactcctggt ccgccccgcc	60
	atgtctgaag aggaatgtat gcattgcagt ggagaaaact atgacggcaa aatttccaag	120
	accatgtctg gactggaatg ccaggcctgg gactctcaga gccacacgc tcatggatac	180
5	attccttcca aatttccaaa caagaacctg aagaagaatt actgtcgtaa ccccgatagg	240
	gagctgcggc cttggtgttt caccaccgac cccaacaagc gctgggaact ttgtgacatc	300
	ccccgctgca caacacctcc accatcttct ggteccacct accagtgtct gaagggaaca	360
	ggtgaaaact atcgcgggaa tgtggctgtt accgtgtccg ggcacacctg tcagcactgg	420
	agtgcacaga cccctcacac acataacagg acaccagaaa acttccccctg caaaaatttg	480
10	gatgaaaact actgccgcaa tctgacgga aaaagggccc catggtgcca tacaaccaac	540
	agccaagtgc ggtgggagta ctgtaagata ccgtcctgtg actcctcccc agtatccacg	600
	gaacaattgg cttgaaagct tggatcc	627
	<210> 42	
15	<211> 1154	
	<212> DNA	
	<213> human	
	<400> 42	
20	ccatgtcact gtttgaaaaa aaagtttatc tctcagagtg caagactggg aatggaaaga	60
	attacagagg gacgatgtcc aaaacaaaaa atggcatcac ctgtcaaaaa tggagtcca	120
	cttctcccca cagacctaga ttctcacctg ctacacaccc ctacagaggga ctggaggaga	180
	actactgcag gaatccagac aacgatccgc agggggccctg gtgctatact actgatccag	240
	aaaagagata tgactactgc gacattcttg agtgtgaaga ggaatgtatg cattgcagtg	300
25	gagaaaacta tgacggcaaa atttccaaga ccatgtcttg actggaatgc caggcctggg	360
	actctcagag cccacacgct catggataca ttcttccaa atttccaaac aagaacctga	420
	agaagaatta ctgtcgtaac cccgataggg agctgcggcc ttggtgtttc accaccgacc	480
	ccaacaagcg ctgggaactt tgtgacatcc cccgctgcac aacacctcca ccatcttctg	540
	gtccaccta ccagtgtctg aagggaaacag gtgaaaacta tcgcggggaat gtggctgtta	600
30	ccgtgtccgg gcacacctgt cagcactgga gtgcacagac cctcacaca cataacagga	660
	caccagaaaa cttccccctgc aaaaatttgg atgaaaacta ctgccgcaat cctgacggaa	720
	aaagggcccc atggtgccat acaaccaaca gccaaagtgcg gtgggagtac tgtaagatac	780
	cgtcctgtga ctctcccca gtatccacgg aacagttggc tcccacagca ccacctgagc	840
	taaccctgt ggtccaggac tgctaccatg gtgatggaca gagctaccga ggcacatcct	900
35	ccaccaccac cacaggaaag aagtgtcagt cttggtcatc tatgacacca caccggcacc	960
	agaagacccc agaaaactac ccaaatgctg gcctgacaat gaactactgc aggaatccag	1020
	atgccgataa aggccccctg tgttttacca cagaccccag cgtcaggtgg gagtactgca	1080
	acctgaaaaa atgctcagga acagaagcga gtgttgtagc acctccgct gttgtcctgc	1140
	tttaataaaa gctt	1154
40	<210> 43	
	<211> 1106	
	<212> DNA	
	<213> human	
45	<400> 43	
	ccatgtcagt gtatctgtcc gagtgaaga ctgggaatgg aaagaattac agagggacga	60
	tgtccaaaac aaaaaatggc atcacctgtc aaaaatggag ttccacttct cccacagac	120
	ctagattctc acctgctaca caccctcag agggactgga ggagaactac tgcaggaaac	180
50	cagacaacga tccgcagggg ccttggtgct atactactga tccagaaaag agatatgact	240
	actgcgacat tcttgagtgt gaagaggaaat gtatgcattg cagtggagaa aactatgacg	300
	gcaaaatttc caagaccatg tctggactgg aatgccaggc ctgggactct cagagcccac	360
	acgctcatgg atacattcct tccaaatttc caaacaagaa cctgaagaag aattactgtc	420
	gtaaccccca tagggagctg cggccttggg gtttcaccac cgaccccaac aagcgctggg	480

WO 99/16889

- 13 -

PCT/US98/20464

	aactttgtga catccccgc tgcacaacac ctccaccatc ttctgggtccc acctaccagt	540
	gtctgaaggg aacaggtgaa aactatcgcg ggaatgtggc tgttaccgtg tccgggcaca	600
	cctgtcagca ctggagtgc cagacccctc acacacataa caggacacca gaaaacttcc	660
	cctgcaaaaa tttggatgaa aactactgcc gcaatcctga cggaaaaagg gccccatggt	720
5	gccatacaac caacagccaa gtgcggtggg agtactgtaa gataccgtcc tgtgactcct	780
	ccccagtatc cacggaacag ttgggtccca cagcaccacc tgagctaacc cctgtggtcc	840
	aggactgcta ccatggtgat ggacagagct accgaggcac atcctccacc accaccacag	900
	gaaagaagtg tcagtcttgg tcacttatga caccacaccg gcaccagaag accccagaaa	960
	actacccaaa tgetggcctg acaatgaact actgcaggaa tccagatgcc gataaaggcc	1020
10	cctgggtgttt taccacagac cccagcgtca ggtgggagta ctgcaacctg aaaaaatgct	1080
	caggaacaga agcgtataaa aagctt	1106

<210> 44

<211> 566

15 <212> DNA

<213> human

<400> 44

	ccatgtctga agaagaatgc atgcactgca gtggagaaaa ctatgacggc aaaattttcca	60
20	agaccatgtc tggactggaa tgccaggcct gggactctca gagcccacac gctcatggat	120
	acattccttc caaattttcca aacaagaacc tgaagaagaa ttactgtcgt aaccccata	180
	gggagctgcg gccttgggtgt ttcaccaccg accccaacaa gcgctgggaa ctttgtgaca	240
	tcccccgctg cacaacacct ccaccatctt ctgggtccac ctaccagtgt ctgaagggaa	300
	caggtgaaaa ctatcgcggtg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	360
25	ggagtgcaca gacccctcac acacataaca ggacaccaga aaacttcccc tgcaaaaatt	420
	tggatgaaaa ctactgccgc aatcctgacg gaaaaagggc cccatgggtgc catacaacca	480
	acagccaagt gcggtgggag tactgtaaga taccgtcctg tgactcctcc ccagtatcca	540
	cggaacaatt ggcttaataa aagctt	566

30 <210> 45

<211> 854

<212> DNA

<213> human

35 <400> 45

	ccatgtctga ggaagaatgc atgcactgca gtggagaaaa ctatgacggc aaaattttcca	60
	agaccatgtc tggactggaa tgccaggcct gggactctca gagcccacac gctcatggat	120
	acattccttc caaattttcca aacaagaacc tgaagaagaa ttactgtcgt aaccccata	180
	gggagctgcg gccttgggtgt ttcaccaccg accccaacaa gcgctgggaa ctttgtgaca	240
40	tcccccgctg cacaacacct ccaccatctt ctgggtccac ctaccagtgt ctgaagggaa	300
	caggtgaaaa ctatcgcggtg aatgtggctg ttaccgtgtc cgggcacacc tgtcagcact	360
	ggagtgcaca gacccctcac acacataaca ggacaccaga aaacttcccc tgcaaaaatt	420
	tggatgaaaa ctactgccgc aatcctgacg gaaaaagggc cccatgggtgc catacaacca	480
	acagccaagt gcggtgggag tactgtaaga taccgtcctg tgactcctcc ccagtatcca	540
45	cggaacagtt ggctcccaca gcaccacctg agctaaccac tgtggtccag gactgctacc	600
	atggtgatgg acagagctac cgaggcacat cctccaccac caccacagga aagaagtgtc	660
	agtcttggtc atctatgaca ccacaccggc accagaagac cccagaaaac taccctaatg	720
	ctggcctgac aatgaactac tgcaggaatc cagatgccga taaaggcccc tgggtgttta	780
	ccacagaccc cagcgtcagg tgggagtact gcaacctgaa aaaatgctca ggaacagaag	840
50	cgtaataaaa gctt	854

<210> 46

<211> 818

<212> DNA

WO 99/16889

- 14 -

PCT/US98/20464

<213> human

<400> 46

5 ccatgtcagt ttatctttca gagtgtgaaga ctgggaatgg aaagaattac agagggacga 60
 tgtccaaaac aaaaaatggc atcacctgtc aaaaatggag ttccacttct cccacagac 120
 ctagattctc acctgctaca caccctcag agggactgga ggagaactac tgcaggaatc 180
 cagacaacga tccgcagggg ccctggtgct atactactga tccagaaaag agatatgact 240
 actgcgacat tcttgagtgt gaagaggaat gtatgcattg cagtggagaa aactatgacg 300
 gcaaaatttc caagaccatg tctggactgg aatgccaggc ctgggactct cagagccac 360
 10 acgctcatgg atacattcct tccaaatttc caacaagaa cctgaagaag aattactgtc 420
 gtaaccccgga tagggagctg cggccttggg gtttcaccac cgacccaac aagcgtggg 480
 aactttgtga catccccgc tgcacaacac ctccaccatc ttctgggtcc acctaccagt 540
 gtctgaaggg aacaggtgaa aactatcgcg ggaatgtggc tgttaccgtg tccgggcaca 600
 cctgtcagca ctggagtgc cagaccctc acacacataa caggacacca gaaaacttcc 660
 15 cctgcaaaaa tttggatgaa aactactgcc gcaatcctga cggaaaaagg gcccctggg 720
 gccatacaac caacagccaa gtgcgggtgg agtactgtaa gataccgtcc tgtgactcct 780
 cccagtatc cccggaacaa ttggcttaat aaaagctt 818

<210> 47

20 <211> 281

<212> DNA

<213> human

<400> 47

25 ccatgtccgt gtacctgtca gaatgtgaaga ctgggaatgg aaagaattac agagggacga 60
 tgtccaaaac aaaaaatggc atcacctgtc aaaaatggag ttccacttct cccacagac 120
 ctagattctc acctgctaca caccctcag agggactgga ggagaactac tgcaggaatc 180
 cagacaacga tccgcagggg ccctggtgct atactactga tccagaaaag agatatgact 240
 actgcgacat tcttgagtgt gaagaggaat aataaaagct t 281

30

<210> 48

<211> 345

<212> DNA

<213> human

35

<400> 48

40 ggatccacca tgagccgcct gcccgctctg ctctgtctcc aactcctggg cggccccgcc 60
 atggccgtgt acctgtcaga atgtaagact gggaatggaa agaattacag agggacgatg 120
 tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct 180
 agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca 240
 gacaacgatc cgcaggggcc ctggtgctat actactgatc cagaaaagag atatgactac 300
 tgcgacattc ttgagtgtga agaggaataa taaaagcttg gatc 345

<210> 49

45 <211> 1436

<212> DNA

<213> human

<400> 49

50 ggatccacca tgagccgcct gcccgctctg ctctgtctcc aactcctggg cggccccgcc 60
 atggcagttt atctttcaga gtgtaagact gggaatggaa agaattacag agggacgatg 120
 tccaaaacaa aaaatggcat cacctgtcaa aaatggagtt ccacttctcc ccacagacct 180
 agattctcac ctgctacaca cccctcagag ggactggagg agaactactg caggaatcca 240
 gacaacgatc cgcaggggcc ctggtgctat actactgatc cagaaaagag atatgactac 300

WO 99/16889

- 15 -

PCT/US98/20464

5	tgcgacattc	ttgagtgtga	agaggaatgt	atgcattgca	gtggagaaaa	ctatgacggc	360
	aaaattttcca	agaccatgtc	tggactggaa	tgccaggcct	gggactctca	gagcccacac	420
	gctcatggat	acattccttc	caaattttcca	aacaagaacc	tgaagaagaa	ttactgtcgt	480
	aacccccgata	gggagctgcg	gccttgggtgt	ttcaccaccg	acccaacaa	gcgctgggaa	540
	ctttgtgaca	tcccccgctg	cacaacacct	ccaccatctt	ctgggtccac	ctaccagtgt	600
10	ctgaagggaa	caggtgaaaa	ctatcgcggt	aatgtggctg	ttaccgtgtc	cgggcacacc	660
	tgtcagcact	ggagtgcaca	gacccctcac	acacataaca	ggacaccaga	aaacttcccc	720
	tgcaaaaatt	tggatgaaaa	ctactgccgc	aatcctgacg	gaaaaagggc	cccttgggtgc	780
	catacaacca	acagccaagt	gcggtgggag	tactgtaaga	taccgtcctg	tgactcctcc	840
	ccagtatcca	cggaacagtt	ggcttacgta	gagggcggtg	gaggctcccc	gggtgggtgt	900
15	tctggcggtg	gctccaacat	ggcttgtgat	ctgccgcaa	ctcatagcct	gggtagccgt	960
	cgcaccctga	tgtgtgtggc	tcagatggcg	cgtatctctc	ttttctcctg	cttgaaggac	1020
	agacatgact	ttggatttcc	ccaggaggag	tttggaacc	agttccaaaa	ggctgaaacc	1080
	atccctgtcc	tccatgagat	gatccagcag	atcttcaacc	tggtttaccac	caaagattct	1140
	tctgtgtctt	gggatgagga	cctgtgtggc	aaattctgca	ccgaactgta	ccagcagctg	1200
20	aacgacctcg	aagcctgtgt	gatgcaggag	gagcgtgtgg	gtgaaactcc	gctgatgaac	1260
	gtggactcca	tcctggctgt	gaagaaatac	ttccgtcgta	tcactctgta	tctgactgag	1320
	aagaaataca	gcccgtgtgc	ttgggaggtt	gttcgtgtcg	aaatcatgcg	ttccctgtct	1380
	ctgtctacca	acctgcaaga	acgtctgcgt	cgtaaggaat	aataaagctt	ggatcc	1436
	<210> 50						
25	<211> 552						
	<212> DNA						
	<213> human						
	<400> 50						
30	cacagccacc	gcgacttcca	gccggtgtgc	cacctgggtg	cgctcaacag	ccccctgtca	60
	ggcggcatgc	ggggcatccg	cggggccgac	ttccagtgtc	tccagcaggc	gcggggccgtg	120
	gggctggcgg	gcaccttccg	cgccttctctg	tcctcgcgcc	tgcaggacct	gtacagcatc	180
	gtgcgccgtg	ccgaccggcg	agccgtgccc	atcgtcaacc	tcaaggacga	gctgctgttt	240
	cccagctggg	aggtctctgt	ctcaggtctc	gaggggtccg	tgaagcccg	ggcacgcac	300
35	ttctcctttg	acggcaagga	cgtcctgagg	cacccacact	ggccccagaa	gagcgtgtgg	360
	catggctcgg	acccaacgg	gcgcaggctg	accgagagct	actgtgagac	gtggcggacg	420
	gaggctccct	cggccacggg	ccaggcctcc	tcgctgtgtg	ggggcaggct	cctggggcag	480
	agtgccgcga	gctgccatca	cgcctacatc	gtgctctgca	ttgagaacag	cttcatgact	540
	gcctccaagt	ag					552
40	<210> 51						
	<211> 2732						
	<212> DNA						
	<213> human						
	<400> 51						
45	aacaacatcc	tgggattggg	accacttttc	tgggcactgc	tggccagtc	caaatggaa	60
	cataaggaag	tggttcttct	acttctttta	tttctgaaat	caggtcaagg	agagcctctg	120
	gatgactatg	tgaataccca	gggggttcca	ctgttcagt	tcactaagaa	gcagctggga	180
	gcaggaagta	tagaagaatg	tgcagcaaaa	tgtgaggagg	acgaagaatt	cacctgcagg	240
	gcattccaat	atcacagtaa	agagcaacaa	tgtgtgataa	tggctgaaaa	caggaagtcc	300
50	tccataatca	ttaggatgag	agatgtagtt	ttatttgaaa	agaaagtgt	tctctcagag	360
	tgcaagactg	ggaatggaaa	gaattacaga	gggacgatgt	ccaaaacaaa	aatggcatc	420
	acctgtcaaa	aatggagtcc	cacttctccc	cacagacct	gattctcacc	tgctacacac	480
	ccctcagagg	gactggagga	gaactactgc	aggaatccag	acaacgatcc	gcagggggccc	540
	tgggtgtata	ctactgatcc	agaaaagaga	tatgactact	gcgacattct	tgagtgtgaa	600
55	gaggaatgta	tgcattgcag	tggagaaaac	tatgacggca	aaatttccaa	gaccatgtct	660

WO 99/16889

- 16 -

PCT/US98/20464

	ggactggaat gccaggcctg ggactctcag agcccacacg ctcatggata cattccttcc	720
	aaattttccaa acaagaacct gaagaagaat tactgtcgta accccgatag ggagctgcgg	780
	ccttgggtgtt tcaccaccga ccccaacaag cgctgggaac tttgtgacat ccccgctgc	840
	acaacacctc caccatcttc tgggtcccacc taccagtgtc tgaagggaac aggtgaaaac	900
5	tatcgcgggga atgtggctgt taccgtgtcc gggcacacct gtcagcactg gagtgacag	960
	accctcaca cacataacag gacaccagaa aacttcccct gcaaaaattt ggatgaaaac	1020
	tactgccgca atcctgacgg aaaaagggcc ccattggtgcc atacaaccaa cagccaagtg	1080
	cggtgggagt actgtaagat accgtcctgt gactcctccc cagtatccac ggaacagttg	1140
	gctcccacag caccacctga gctaaccctt gtgggtccagg actgctacca tggatgatgga	1200
10	cagagctacc gaggcacatc ctccaccacc accacaggaa agaagtgtca gtcttgggtca	1260
	tctatgacac cacaccggca ccagaagacc ccagaaaact acccaaattg tggcctgaca	1320
	atgaactact gcaggaatcc agatgccgat aaaggcccct ggtgttttac cacagacccc	1380
	agcgtcaggt gggagtactg caacctgaaa aaatgctcag gaacagaagc gagtggtgta	1440
	gcacctccgc ctgttgtcct gcttccagat gtagagactc cttccgaaga agactgtatg	1500
15	tttgggaatg ggaaaggata ccgaggcaag agggcgacca ctgttactgg gacgccatgc	1560
	caggactggg ctgcccagga gcccacataga cacagcattt tccctccaga gacaaatcca	1620
	cgggcgggtc tggaaaaaaa ttactgccgt aacctgatg gtgatgtagg tggcctctgg	1680
	tgctacacga caaatccaag aaaactttac gactactgtg atgtccctca gtgtgcggcc	1740
	ccttcatttg attgtgggaa gcctcaagtg gagccgaaga aatgtcctgg aagggttggtg	1800
20	gggggggtgtg tggcccaccc acattcctgg ccctggcaag tcagtcttag aacaaggttt	1860
	ggaatgcact tctgtggagg caccttgata tcccagagt ggggtgtgac tgctgccac	1920
	tgcttgagga agtccccaag gccttcatcc tacaaggtea tcctgggtgc acaccaagaa	1980
	gtgaatctcg aaccgcatgt tcaggaaata gaagtgtcta ggctgttctt ggagcccaca	2040
	cgaaaagata ttgccttgct aaagctaagc agtcctgcgc tcactactga caaagtaatc	2100
25	ccagcttgte tgccatcccc aaattatgtg gtcgctgacc ggaccgaatg tttcatcact	2160
	ggctggggag aaaccaagg tacttttgga gctggccttc tcaaggagc ccagctccct	2220
	gtgattgaga ataaagtgtg caatcgctat gagtttctga atggaagagt ccaatccacc	2280
	gaactctgtg ctgggcattt ggccggaggc actgacagtt gccagggtga cagtggaggt	2340
	cctctggttt gcttcgagaa ggacaaatac attttacaag gagtcacttc ttgggggtctt	2400
30	ggctgtgcac gcccacataa gcctgggtgtc tatgttcgtg tttcaagggt tgttacttgg	2460
	attgagggag tgatgagaaa taattaattg gacgggagac agagtgcgc actgactcac	2520
	ctagaggctg ggacgtgggt agggatttag catgctggaa ataactggca gtaatcaaac	2580
	gaagacactg tcccagcta ccagctacgc caaacctcgg cattttttgt gttattttct	2640
	gactgctgga ttctgtagta aggtgacata gctatgacat ttgttaaaaa taaactctgt	2700
35	acttaacttt gatttgagta aattttggtt tt	2732

<210> 52

<211> 384

<212> DNA

40

<213> human

<400> 52

	ggccctacgg gcaccggtga atccaagtgt cctctgatgg tcaaagttct agatgctgtc	60
	cgaggcagtc ctgccatcaa tgtggccgtg catgtgttca gaaaggctgc tgatgacacc	120
45	tgggagccat ttgcctctgg gaaaaccagt gagtctggag agctgcatgg gctcacaact	180
	gaggaggaat ttgtagaagg gatatacaaa gtggaaatag acaccaaata ttactggaag	240
	gcacttgga totccccatt ccatgagcat gcagagggtg tattcacagc caacgactcc	300
	ggcccccgcc gctacaccat tgccgccctg ctgagcccct actcctattc caccacggct	360
	gtcgtcacca atcccaagga atga	384

50

<210> 53

<211> 165

<212> PRT

<213> human

WO 99/16889

- 17 -

PCT/US98/20464

<400> 53

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 1 5 10 15

5 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
 35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 50 55 60

10 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
 65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 85 90 95

15 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 130 135 140

20 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 145 150 155 160

Leu Arg Ser Lys Glu
 165

25

<210> 54
 <211> 165
 <212> PRT
 <213> human

30

<400> 54

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met
 1 5 10 15

35 Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp
 20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln
 35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe
 50 55 60

40 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu
 65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu
 85 90 95

45 Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 130 135 140

50 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 145 150 155 160

Leu Arg Ser Lys Glu
 165

WO 99/16889

- 18 -

PCT/US98/20464

<210> 55
 <211> 274
 <212> PRT
 <213> human

5

<400> 55

Met Ala Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr
 1 5 10 15
 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu
 20 25 30
 Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln
 35 40 45
 Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln
 50 55 60
 Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu
 65 70 75 80
 Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp
 85 90 95
 Leu Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu
 100 105 110
 Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile
 115 120 125
 Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val
 130 135 140
 Val Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln
 145 150 155 160
 Glu Arg Leu Arg Arg Lys Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro
 165 170 175
 Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Glu
 180 185 190
 Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr
 195 200 205
 Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg
 210 215 220
 Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn
 225 230 235 240
 Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr
 245 250 255
 Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu
 260 265 270
 Glu Glu

<210> 56
 <211> 453
 <212> PRT
 <213> human

50

<400> 56

Met Ala Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr
 1 5 10 15
 Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu
 20 25 30
 Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

WO 99/16889

- 19 -

PCT/US98/20464

	35	40	45
	Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln		
	50	55	60
5	Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu		
	65	70	75
	Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp		
	85	90	95
	Leu Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu		
	100	105	110
10	Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile		
	115	120	125
	Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val		
	130	135	140
	Val Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln		
15	145	150	155
	Glu Arg Leu Arg Arg Lys Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro		
	165	170	175
	Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Glu		
	180	185	190
20	Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr		
	195	200	205
	Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg		
	210	215	220
	Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn		
25	225	230	235
	Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr		
	245	250	255
	Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu		
	260	265	270
30	Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser		
	275	280	285
	Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro		
	290	295	300
	His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys		
35	305	310	315
	Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe		
	325	330	335
	Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys		
	340	345	350
40	Thr Thr Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly		
	355	360	365
	Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His		
	370	375	380
	Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr		
45	385	390	395
	Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn		
	405	410	415
	Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val		
	420	425	430
50	Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser		
	435	440	445
	Thr Glu Gln Leu Ala		
	450		

WO 99/16889

- 20 -

PCT/US98/20464

<210> 57
 <211> 274
 <212> PRT
 <213> human

5

<400> 57

Met	Ala	Cys	Asp	Leu	Pro	Gln	Thr	His	Ser	Leu	Gly	Ser	Arg	Arg	Thr
1				5					10					15	
Leu	Met	Leu	Leu	Ala	Gln	Met	Arg	Arg	Ile	Ser	Leu	Phe	Ser	Cys	Leu
			20				25						30		
Lys	Asp	Arg	His	Asp	Phe	Gly	Phe	Pro	Gln	Glu	Glu	Phe	Gly	Asn	Gln
		35					40						45		
Phe	Gln	Lys	Ala	Glu	Thr	Ile	Pro	Val	Leu	His	Glu	Met	Ile	Gln	Gln
	50					55					60				
Ile	Phe	Asn	Leu	Phe	Ser	Thr	Lys	Asp	Ser	Ser	Ala	Ala	Trp	Asp	Glu
65					70				75					80	
Thr	Leu	Leu	Asp	Lys	Phe	Tyr	Thr	Glu	Leu	Tyr	Gln	Gln	Leu	Asn	Asp
			85						90					95	
Leu	Glu	Ala	Cys	Val	Ile	Gln	Gly	Val	Gly	Val	Thr	Glu	Thr	Pro	Leu
		100						105					110		
Met	Lys	Glu	Asp	Ser	Ile	Leu	Ala	Val	Arg	Lys	Tyr	Phe	Gln	Arg	Ile
		115					120						125		
Thr	Leu	Tyr	Leu	Lys	Glu	Lys	Lys	Tyr	Ser	Pro	Cys	Ala	Trp	Glu	Val
	130					135					140				
Val	Arg	Ala	Glu	Ile	Met	Arg	Ser	Phe	Ser	Leu	Ser	Thr	Asn	Leu	Gln
145					150				155					160	
Glu	Ser	Leu	Arg	Ser	Lys	Glu	Tyr	Val	Glu	Gly	Gly	Gly	Gly	Ser	Pro
			165					170					175		
Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Asn	Met	Ala	Val	Tyr	Leu	Ser	Glu
		180					185						190		
Cys	Lys	Thr	Gly	Asn	Gly	Lys	Asn	Tyr	Arg	Gly	Thr	Met	Ser	Lys	Thr
		195					200					205			
Lys	Asn	Gly	Ile	Thr	Cys	Gln	Lys	Trp	Ser	Ser	Thr	Ser	Pro	His	Arg
	210					215					220				
Pro	Arg	Phe	Ser	Pro	Ala	Thr	His	Pro	Ser	Glu	Gly	Leu	Glu	Glu	Asn
225					230				235					240	
Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro	Gln	Gly	Pro	Trp	Cys	Tyr	Thr
			245					250					255		
Thr	Asp	Pro	Glu	Lys	Arg	Tyr	Asp	Tyr	Cys	Asp	Ile	Leu	Glu	Cys	Glu
		260						265					270		
Glu	Glu														

<210> 58
 <211> 453
 <212> PRT
 <213> human

50

<400> 58

Met	Ala	Cys	Asp	Leu	Pro	Gln	Thr	His	Ser	Leu	Gly	Ser	Arg	Arg	Thr
1				5					10					15	
Leu	Met	Leu	Leu	Ala	Gln	Met	Arg	Arg	Ile	Ser	Leu	Phe	Ser	Cys	Leu
			20					25					30		
Lys	Asp	Arg	His	Asp	Phe	Gly	Phe	Pro	Gln	Glu	Glu	Phe	Gly	Asn	Gln

WO 99/16889

- 21 -

PCT/US98/20464

	35	40	45
	Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln		
	50	55	60
5	Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu		
	65	70	75
	Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp		80
	85	90	95
	Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu		
	100	105	110
10	Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile		
	115	120	125
	Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val		
	130	135	140
	Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln		
15	145	150	155
	Glu Ser Leu Arg Ser Lys Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro		160
	165	170	175
	Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Val Tyr Leu Ser Glu		
	180	185	190
20	Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr		
	195	200	205
	Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg		
	210	215	220
	Pro Arg Phe Ser Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn		
25	225	230	235
	Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr		240
	245	250	255
	Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys Asp Ile Leu Glu Cys Glu		
	260	265	270
30	Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly Lys Ile Ser		
	275	280	285
	Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser Gln Ser Pro		
	290	295	300
	His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys Asn Leu Lys		
35	305	310	315
	Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro Trp Cys Phe		320
	325	330	335
	Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile Pro Arg Cys		
	340	345	350
40	Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln Cys Leu Lys Gly		
	355	360	365
	Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr Val Ser Gly His		
	370	375	380
	Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr His Asn Arg Thr		
45	385	390	395
	Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn Tyr Cys Arg Asn		400
	405	410	415
	Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr Asn Ser Gln Val		
	420	425	430
50	Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser Ser Pro Val Ser		
	435	440	445
	Thr Glu Gln Leu Ala		
	450		

WO 99/16889

- 22 -

PCT/US98/20464

<210> 59
 <211> 453
 <212> PRT
 <213> human

5

<400> 59

	Met	Ala	Val	Tyr	Leu	Ser	Glu	Cys	Lys	Thr	Gly	Asn	Gly	Lys	Asn	Tyr
	1				5					10					15	
	Arg	Gly	Thr	Met	Ser	Lys	Thr	Lys	Asn	Gly	Ile	Thr	Cys	Gln	Lys	Trp
10				20					25					30		
	Ser	Ser	Thr	Ser	Pro	His	Arg	Pro	Arg	Phe	Ser	Pro	Ala	Thr	His	Pro
			35					40					45			
	Ser	Glu	Gly	Leu	Glu	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro
		50					55					60				
15	Gln	Gly	Pro	Trp	Cys	Tyr	Thr	Thr	Asp	Pro	Glu	Lys	Arg	Tyr	Asp	Tyr
	65					70					75				80	
	Cys	Asp	Ile	Leu	Glu	Cys	Glu	Glu	Glu	Cys	Met	His	Cys	Ser	Gly	Glu
				85						90					95	
	Asn	Tyr	Asp	Gly	Lys	Ile	Ser	Lys	Thr	Met	Ser	Gly	Leu	Glu	Cys	Gln
20				100					105					110		
	Ala	Trp	Asp	Ser	Gln	Ser	Pro	His	Ala	His	Gly	Tyr	Ile	Pro	Ser	Lys
			115					120					125			
	Phe	Pro	Asn	Lys	Asn	Leu	Lys	Lys	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Arg
		130				135					140					
25	Glu	Leu	Arg	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro	Asn	Lys	Arg	Trp	Glu
	145					150				155					160	
	Leu	Cys	Asp	Ile	Pro	Arg	Cys	Thr	Thr	Pro	Pro	Pro	Ser	Ser	Gly	Pro
				165						170					175	
	Thr	Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Glu	Asn	Tyr	Arg	Gly	Asn	Val
30				180					185					190		
	Ala	Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr
		195						200					205			
	Pro	His	Thr	His	Asn	Arg	Thr	Pro	Glu	Asn	Phe	Pro	Cys	Lys	Asn	Leu
		210				215					220					
35	Asp	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys
	225				230					235					240	
	His	Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Glu	Tyr	Cys	Lys	Ile	Pro	Ser
				245					250					255		
	Cys	Asp	Ser	Ser	Pro	Val	Ser	Thr	Glu	Gln	Leu	Ala	Tyr	Val	Glu	Gly
40				260					265					270		
	Gly	Gly	Gly	Ser	Pro	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Ser	Asn	Met	Ala
		275						280					285			
	Cys	Asp	Leu	Pro	Gln	Thr	His	Ser	Leu	Gly	Ser	Arg	Arg	Thr	Leu	Met
		290				295					300					
45	Leu	Leu	Ala	Gln	Met	Arg	Arg	Ile	Ser	Leu	Phe	Ser	Cys	Leu	Lys	Asp
	305				310					315					320	
	Arg	His	Asp	Phe	Gly	Phe	Pro	Gln	Glu	Glu	Phe	Gly	Asn	Gln	Phe	Gln
				325					330					335		
	Lys	Ala	Glu	Thr	Ile	Pro	Val	Leu	His	Glu	Met	Ile	Gln	Gln	Ile	Phe
50				340					345					350		
	Asn	Leu	Phe	Ser	Thr	Lys	Asp	Ser	Ser	Ala	Ala	Trp	Asp	Glu	Thr	Leu
		355					360						365			
	Leu	Asp	Lys	Phe	Tyr	Thr	Glu	Leu	Tyr	Gln	Gln	Leu	Asn	Asp	Leu	Glu
		370					375					380				

WO 99/16889

- 23 -

PCT/US98/20464

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys
 385 390 395 400
 Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu
 405 410 415
 5 Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg
 420 425 430
 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser
 435 440 445
 Leu Arg Ser Lys Glu
 10 450

 <210> 60
 <211> 274
 <212> PRT
 15 <213> human

 <400> 60
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 20 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 25 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu Tyr Val Glu Gly Gly Gly Gly
 85 90 95
 30 Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Cys Asp Leu
 100 105 110
 Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu Leu Ala
 115 120 125
 Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg His Asp
 35 130 135 140
 Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu
 145 150 155 160
 Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn Leu Phe
 165 170 175
 40 Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu Leu Asp Lys
 180 185 190
 Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val
 195 200 205
 Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met Asn Val Asp Ser
 45 210 215 220
 Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu Tyr Leu Thr
 225 230 235 240
 Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile
 245 250 255
 50 Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg Leu Arg Arg
 260 265 270
 Lys Glu

WO 99/16889

- 24 -

PCT/US98/20464

<210> 61
 <211> 274
 <212> PRT
 <213> human

5

<400> 61
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 10 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 15 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu Tyr Val Glu Gly Gly Gly Gly
 85 90 95
 Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Cys Asp Leu
 100 105 110
 Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu Leu Ala
 115 120 125
 Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg His Asp
 130 135 140
 Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln Lys Ala Glu
 145 150 155 160
 Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn Leu Phe
 165 170 175
 Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu Leu Asp Lys
 180 185 190
 Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala Cys Val
 195 200 205
 Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys Glu Asp Ser
 210 215 220
 Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu Tyr Leu Lys
 225 230 235 240
 Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala Glu Ile
 245 250 255
 Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser Leu Arg Ser
 260 265 270
 Lys Glu

<210> 62
 <211> 453
 <212> PRT
 <213> human

<400> 62
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro

WO 99/16889

- 25 -

PCT/US98/20464

	35		40		45
	Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro				
	50		55		60
5	Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr				
	65		70		75
	Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu				
		85		90	
	Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln				
		100		105	
10	Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys				
		115		120	
	Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg				
		130		135	
	Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu				
15		145		150	
				155	
	Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro				
		165		170	
	Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val				
		180		185	
20	Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr				
		195		200	
	Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu				
		210		215	
	Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys				
25		225		230	
				235	
	His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser				
		245		250	
	Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Tyr Val Glu Gly				
		260		265	
30	Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala				
		275		280	
				285	
	Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met				
		290		295	
				300	
	Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp				
35		305		310	
				315	
	Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln				
		325		330	
	Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe				
		340		345	
40	Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp Leu				
		355		360	
				365	
	Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu				
		370		375	
				380	
	Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met Asn				
45		385		390	
				395	
	Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr Leu				
		405		410	
				415	
	Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg				
		420		425	
				430	
50	Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu Arg				
		435		440	
				445	
	Leu Arg Arg Lys Glu				
		450			

WO 99/16889

- 26 -

PCT/US98/20464

<210> 63
 <211> 566
 <212> PRT
 <213> human

5

<400> 63

	Met	Glu	His	Lys	Glu	Val	Val	Leu	Leu	Leu	Leu	Phe	Leu	Lys	Ser	
	1				5				10					15		
10	Gly	Gln	Gly	Glu	Pro	Leu	Asp	Asp	Tyr	Val	Asn	Thr	Gln	Gly	Ala	Ser
				20				25					30			
	Leu	Phe	Ser	Val	Thr	Lys	Lys	Gln	Leu	Gly	Ala	Gly	Ser	Ile	Glu	Glu
		35					40					45				
	Cys	Ala	Ala	Lys	Cys	Glu	Glu	Asp	Glu	Glu	Phe	Thr	Cys	Arg	Ala	Phe
	50					55					60					
15	Gln	Tyr	His	Ser	Lys	Glu	Gln	Gln	Cys	Val	Ile	Met	Ala	Glu	Asn	Arg
	65					70				75					80	
	Lys	Ser	Ser	Ile	Ile	Ile	Arg	Met	Arg	Asp	Val	Val	Leu	Phe	Glu	Lys
				85				90					95			
	Lys	Val	Tyr	Leu	Ser	Glu	Cys	Lys	Thr	Gly	Asn	Gly	Lys	Asn	Tyr	Arg
20				100				105					110			
	Gly	Thr	Met	Ser	Lys	Thr	Lys	Asn	Gly	Ile	Thr	Cys	Gln	Lys	Trp	Ser
		115					120					125				
	Ser	Thr	Ser	Pro	His	Arg	Pro	Arg	Phe	Ser	Pro	Ala	Thr	His	Pro	Ser
	130					135						140				
25	Glu	Gly	Leu	Glu	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Asn	Asp	Pro	Gln
	145					150				155					160	
	Gly	Pro	Trp	Cys	Tyr	Thr	Thr	Asp	Pro	Glu	Lys	Arg	Tyr	Asp	Tyr	Cys
				165				170					175			
	Asp	Ile	Leu	Glu	Cys	Glu	Glu	Glu	Cys	Met	His	Cys	Ser	Gly	Glu	Asn
30				180				185					190			
	Tyr	Asp	Gly	Lys	Ile	Ser	Lys	Thr	Met	Ser	Gly	Leu	Glu	Cys	Gln	Ala
		195					200					205				
	Trp	Asp	Ser	Gln	Ser	Pro	His	Ala	His	Gly	Tyr	Ile	Pro	Ser	Lys	Phe
	210					215						220				
35	Pro	Asn	Lys	Asn	Leu	Lys	Lys	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Arg	Glu
	225					230				235					240	
	Leu	Arg	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro	Asn	Lys	Arg	Trp	Glu	Leu
				245				250					255			
	Cys	Asp	Ile	Pro	Arg	Cys	Thr	Thr	Pro	Pro	Pro	Ser	Ser	Gly	Pro	Thr
40				260				265					270			
	Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Glu	Asn	Tyr	Arg	Gly	Asn	Val	Ala
		275					280					285				
	Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His	Trp	Ser	Ala	Gln	Thr	Pro
	290					295						300				
45	His	Thr	His	Asn	Arg	Thr	Pro	Glu	Asn	Phe	Pro	Cys	Lys	Asn	Leu	Asp
	305					310				315					320	
	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys	Arg	Ala	Pro	Trp	Cys	His
				325				330					335			
	Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Glu	Tyr	Cys	Lys	Ile	Pro	Ser	Cys
50				340				345					350			
	Asp	Ser	Ser	Pro	Val	Ser	Thr	Glu	Gln	Leu	Ala	Pro	Thr	Ala	Pro	Pro
		355						360					365			
	Glu	Leu	Thr	Pro	Val	Val	Gln	Asp	Cys	Tyr	His	Gly	Asp	Gly	Gln	Ser
	370						375					380				

WO 99/16889

- 27 -

PCT/US98/20464

Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser
 385 390 395 400
 Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr
 405 410 415
 5 Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp
 420 425 430
 Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr
 435 440 445
 Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro
 10 450 455 460
 Pro Pro Val Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp
 465 470 475 480
 Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr
 485 490 495
 15 Val Thr Gly Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg
 500 505 510
 His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys
 515 520 525
 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr
 20 530 535 540
 Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys
 545 550 555 560
 Ala Ala Pro Ser Phe Asp
 565
 25
 <210> 64
 <211> 381
 <212> PRT
 <213> human
 30
 <400> 64
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 Ala Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 35 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 50 55 60
 40 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly
 45 100 105 110
 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 115 120 125
 Gln Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser
 130 135 140
 50 Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp
 145 150 155 160
 Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
 165 170 175
 Glu Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly

WO 99/16889

- 28 -

PCT/US98/20464

	180	185	190
	Pro Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn		
	195	200	205
5	Val Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln		
	210	215	220
	Thr Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn		
	225	230	235
	Leu Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp		
	245	250	255
10	Cys His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro		
	260	265	270
	Ser Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala		
	275	280	285
	Pro Pro Glu Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly		
15	290	295	300
	Gln Ser Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys		
	305	310	315
	Gln Ser Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu		
	325	330	335
20	Asn Tyr Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp		
	340	345	350
	Ala Asp Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp		
	355	360	365
	Glu Tyr Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala		
25	370	375	380
	<210> 65		
	<211> 285		
	<212> PRT		
30	<213> human		
	<400> 65		
	Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro		
	1	5	10
35	Ala Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn		
	20	25	30
	Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys		
	35	40	45
	Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His		
40	50	55	60
	Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp		
	65	70	75
	Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp		
	85	90	95
45	Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly		
	100	105	110
	Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys		
	115	120	125
	Gln Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser		
50	130	135	140
	Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp		
	145	150	155
	Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp		
	165	170	175

WO 99/16889

- 29 -

PCT/US98/20464

Glu Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly
 180 185 190
 Pro Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn
 195 200 205
 5 Val Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln
 210 215 220
 Thr Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn
 225 230 235 240
 10 Leu Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp
 245 250 255
 Cys His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro
 260 265 270
 Ser Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala
 275 280 285
 15
 <210> 66
 <211> 297
 <212> PRT
 <213> human
 20
 <400> 66
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 Ala Met Ser Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp
 20 25 30
 25 Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp
 35 40 45
 Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn
 50 55 60
 30 Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg
 65 70 75 80
 Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp
 85 90 95
 35 Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln
 100 105 110
 Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr
 115 120 125
 Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr
 130 135 140
 40 His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn
 145 150 155 160
 Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr
 165 170 175
 45 Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser
 180 185 190
 Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro Glu Leu
 195 200 205
 Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser Tyr Arg
 210 215 220
 50 Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser Trp Ser
 225 230 235 240
 Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr Pro Asn
 245 250 255
 Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp Lys Gly

WO 99/16889

- 30 -

PCT/US98/20464

260 265 270
 Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn
 275 280 285
 Leu Lys Lys Cys Ser Gly Thr Glu Ala
 5 290 295

 <210> 67
 <211> 201
 <212> PRT
 10 <213> human

 <400> 67
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 15 Ala Met Ser Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp
 20 25 30
 Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp
 35 40 45
 Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn
 20 50 55 60
 Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg
 65 70 75 80
 Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp
 85 90 95
 25 Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr Tyr Gln
 100 105 110
 Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala Val Thr
 115 120 125
 Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro His Thr
 30 130 135 140
 His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp Glu Asn
 145 150 155 160
 Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His Thr Thr
 165 170 175
 35 Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys Asp Ser
 180 185 190
 Ser Pro Val Ser Thr Glu Gln Leu Ala
 195 200

 40 <210> 68
 <211> 380
 <212> PRT
 <213> human

 45 <400> 68
 Met Ser Leu Phe Glu Lys Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly
 1 5 10 15
 Asn Gly Lys Asn Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile
 20 25 30
 Thr Cys Gln Lys Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser
 35 40 45
 Pro Ala Thr His Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn
 50 50 55 60
 Pro Asp Asn Asp Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu

	65				70					75					80	
	Lys	Arg	Tyr	Asp	Tyr	Cys	Asp	Ile	Leu	Glu	Cys	Glu	Glu	Glu	Cys	Met
					85					90					95	
5	His	Cys	Ser	Gly	Glu	Asn	Tyr	Asp	Gly	Lys	Ile	Ser	Lys	Thr	Met	Ser
				100					105					110		
	Gly	Leu	Glu	Cys	Gln	Ala	Trp	Asp	Ser	Gln	Ser	Pro	His	Ala	His	Gly
				115				120					125			
	Tyr	Ile	Pro	Ser	Lys	Phe	Pro	Asn	Lys	Asn	Leu	Lys	Lys	Asn	Tyr	Cys
				130			135					140				
10	Arg	Asn	Pro	Asp	Arg	Glu	Leu	Arg	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro
	145					150					155					160
	Asn	Lys	Arg	Trp	Glu	Leu	Cys	Asp	Ile	Pro	Arg	Cys	Thr	Thr	Pro	Pro
				165					170					175		
15	Pro	Ser	Ser	Gly	Pro	Thr	Tyr	Gln	Cys	Leu	Lys	Gly	Thr	Gly	Glu	Asn
				180				185						190		
	Tyr	Arg	Gly	Asn	Val	Ala	Val	Thr	Val	Ser	Gly	His	Thr	Cys	Gln	His
				195				200					205			
	Trp	Ser	Ala	Gln	Thr	Pro	His	Thr	His	Asn	Arg	Thr	Pro	Glu	Asn	Phe
				210			215					220				
20	Pro	Cys	Lys	Asn	Leu	Asp	Glu	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Lys
	225					230				235						240
	Arg	Ala	Pro	Trp	Cys	His	Thr	Thr	Asn	Ser	Gln	Val	Arg	Trp	Glu	Tyr
				245					250						255	
25	Cys	Lys	Ile	Pro	Ser	Cys	Asp	Ser	Ser	Pro	Val	Ser	Thr	Glu	Gln	Leu
				260				265						270		
	Ala	Pro	Thr	Ala	Pro	Pro	Glu	Leu	Thr	Pro	Val	Val	Gln	Asp	Cys	Tyr
				275				280					285			
	His	Gly	Asp	Gly	Gln	Ser	Tyr	Arg	Gly	Thr	Ser	Ser	Thr	Thr	Thr	Thr
				290			295					300				
30	Gly	Lys	Lys	Cys	Gln	Ser	Trp	Ser	Ser	Met	Thr	Pro	His	Arg	His	Gln
	305					310				315						320
	Lys	Thr	Pro	Glu	Asn	Tyr	Pro	Asn	Ala	Gly	Leu	Thr	Met	Asn	Tyr	Cys
				325					330					335		
35	Arg	Asn	Pro	Asp	Ala	Asp	Lys	Gly	Pro	Trp	Cys	Phe	Thr	Thr	Asp	Pro
				340				345						350		
	Ser	Val	Arg	Trp	Glu	Tyr	Cys	Asn	Leu	Lys	Lys	Cys	Ser	Gly	Thr	Glu
				355				360					365			
	Ala	Ser	Val	Val	Ala	Pro	Pro	Pro	Val	Val	Leu	Leu				
				370			375				380					
40																
				<210>	69											
				<211>	364											
				<212												

WO 99/16889

- 32 -

PCT/US98/20464

Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu
 85 90 95
 5 Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln
 100 105 110
 Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys
 115 120 125
 Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg
 10 130 135 140
 Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu
 145 150 155 160
 Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro
 165 170 175
 15 Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val
 180 185 190
 Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr
 195 200 205
 Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu
 20 210 215 220
 Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys
 225 230 235 240
 His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser
 245 250 255
 25 Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro
 260 265 270
 Pro Glu Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln
 275 280 285
 Ser Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln
 30 290 295 300
 Ser Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn
 305 310 315 320
 Tyr Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala
 325 330 335
 35 Asp Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu
 340 345 350
 Tyr Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala
 355 360
 40 <210> 70
 <211> 184
 <212> PRT
 <213> human
 45 <400> 70
 Met Ser Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn Tyr Asp Gly
 1 5 10 15
 Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala Trp Asp Ser
 20 25 30
 50 Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe Pro Asn Lys
 35 40 45
 Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu Leu Arg Pro
 50 55 60
 Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu Cys Asp Ile

WO 99/16889

- 34 -

PCT/US98/20464

Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr Cys Asn Leu
 260 265 270
 Lys Lys Cys Ser Gly Thr Glu Ala
 275 280

5

<210> 72
 <211> 268
 <212> PRT
 <213> human

10

<400> 72
 Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu
 85 90 95
 Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln
 100 105 110
 Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys
 115 120 125
 Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg
 130 135 140
 Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu
 145 150 155 160
 Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro
 165 170 175
 Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val
 180 185 190
 Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr
 195 200 205
 Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu
 210 215 220
 Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys
 225 230 235 240
 His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser
 245 250 255
 Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala
 260 265

15

20

25

30

35

40

45

50

<210> 73
 <211> 89
 <212> PRT
 <213> human

<400> 73
 Met Ser Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15

WO 99/16889

- 35 -

PCT/US98/20464

Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 5 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu
 10 85
 <210> 74
 <211> 106
 <212> PRT
 15 <213> human
 <400> 74
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 20 Ala Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys
 35 40 45
 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 50 55 60
 25 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 30 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu
 100 105
 <210> 75
 <211> 470
 35 <212> PRT
 <213> human
 <400> 75
 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 40 Ala Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn
 20 25 30
 Tyr Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys
 35 40 45
 45 Trp Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His
 50 55 60
 Pro Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp
 65 70 75 80
 Pro Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp
 85 90 95
 50 Tyr Cys Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly
 100 105 110
 Glu Asn Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys
 115 120 125

WO 99/16889

- 36 -

PCT/US98/20464

Gln Ala Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser
 130 135 140
 Lys Phe Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp
 145 150 155 160
 5 Arg Glu Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp
 165 170 175
 Glu Leu Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly
 180 185 190
 Pro Thr Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn
 10 195 200 205
 Val Ala Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln
 210 215 220
 Thr Pro His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn
 225 230 235 240
 15 Leu Asp Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp
 245 250 255
 Cys His Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro
 260 265 270
 Ser Cys Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Tyr Val Glu
 20 275 280 285
 Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met
 290 295 300
 Ala Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu
 305 310 315 320
 25 Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys
 325 330 335
 Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe
 340 345 350
 Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile
 30 355 360 365
 Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 370 375 380
 Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
 385 390 395 400
 35 Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
 405 410 415
 Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
 420 425 430
 Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
 40 435 440 445
 Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 450 455 460
 Arg Leu Arg Arg Lys Glu
 465 470
 45
 <210> 76
 <211> 183
 <212> PRT
 <213> human
 50
 <400> 76
 His Ser His Arg Asp Phe Gln Pro Val Leu His Leu Val Ala Leu Asn
 1 5 10 15
 Ser Pro Leu Ser Gly Gly Met Arg Gly Ile Arg Gly Ala Asp Phe Gln

WO 99/16889

- 37 -

PCT/US98/20464

	20	25	30
	Cys Phe Gln Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Phe Arg Ala		
	35	40	45
5	Phe Leu Ser Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala		
	50	55	60
	Asp Arg Ala Ala Val Pro Ile Val Asn Leu Lys Asp Glu Leu Leu Phe		
	65	70	75
	Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu Gly Pro Leu Lys Pro		
	85	90	95
10	Gly Ala Arg Ile Phe Ser Phe Asp Gly Lys Asp Val Leu Arg His Pro		
	100	105	110
	Thr Trp Pro Gln Lys Ser Val Trp His Gly Ser Asp Pro Asn Gly Arg		
	115	120	125
15	Arg Leu Thr Glu Ser Tyr Cys Glu Thr Trp Arg Thr Glu Ala Pro Ser		
	130	135	140
	Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly Arg Leu Leu Gly Gln		
	145	150	155
	Ser Ala Ala Ser Cys His His Ala Tyr Ile Val Leu Cys Ile Glu Asn		
	165	170	175
20	Ser Phe Met Thr Ala Ser Lys		
	180		
	<210> 77		
	<211> 810		
25	<212> PRT		
	<213> human		
	<400> 77		
30	Met Glu His Lys Glu Val Val Leu Leu Leu Leu Leu Phe Leu Lys Ser		
	1	5	10
	Gly Gln Gly Glu Pro Leu Asp Asp Tyr Val Asn Thr Gln Gly Ala Ser		
	20	25	30
	Leu Phe Ser Val Thr Lys Lys Gln Leu Gly Ala Gly Ser Ile Glu Glu		
	35	40	45
35	Cys Ala Ala Lys Cys Glu Glu Asp Glu Glu Phe Thr Cys Arg Ala Phe		
	50	55	60
	Gln Tyr His Ser Lys Glu Gln Gln Cys Val Ile Met Ala Glu Asn Arg		
	65	70	75
	Lys Ser Ser Ile Ile Ile Arg Met Arg Asp Val Val Leu Phe Glu Lys		
40		85	90
	Lys Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr Arg		
	100	105	110
	Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp Ser		
	115	120	125
45	Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro Ser		
	130	135	140
	Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro Gln		
	145	150	155
	Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr Cys		
50		165	170
	Asp Ile Leu Glu Cys Glu Glu Glu Cys Met His Cys Ser Gly Glu Asn		
	180	185	190
	Tyr Asp Gly Lys Ile Ser Lys Thr Met Ser Gly Leu Glu Cys Gln Ala		
	195	200	205

WO 99/16889

- 38 -

PCT/US98/20464

	Trp Asp Ser Gln Ser Pro His Ala His Gly Tyr Ile Pro Ser Lys Phe	
	210	215 220
	Pro Asn Lys Asn Leu Lys Lys Asn Tyr Cys Arg Asn Pro Asp Arg Glu	
	225	230 235 240
5	Leu Arg Pro Trp Cys Phe Thr Thr Asp Pro Asn Lys Arg Trp Glu Leu	
	245	250 255
	Cys Asp Ile Pro Arg Cys Thr Thr Pro Pro Pro Ser Ser Gly Pro Thr	
	260	265 270
	Tyr Gln Cys Leu Lys Gly Thr Gly Glu Asn Tyr Arg Gly Asn Val Ala	
10	275	280 285
	Val Thr Val Ser Gly His Thr Cys Gln His Trp Ser Ala Gln Thr Pro	
	290	295 300
	His Thr His Asn Arg Thr Pro Glu Asn Phe Pro Cys Lys Asn Leu Asp	
	305	310 315 320
15	Glu Asn Tyr Cys Arg Asn Pro Asp Gly Lys Arg Ala Pro Trp Cys His	
	325	330 335
	Thr Thr Asn Ser Gln Val Arg Trp Glu Tyr Cys Lys Ile Pro Ser Cys	
	340	345 350
	Asp Ser Ser Pro Val Ser Thr Glu Gln Leu Ala Pro Thr Ala Pro Pro	
20	355	360 365
	Glu Leu Thr Pro Val Val Gln Asp Cys Tyr His Gly Asp Gly Gln Ser	
	370	375 380
	Tyr Arg Gly Thr Ser Ser Thr Thr Thr Thr Gly Lys Lys Cys Gln Ser	
	385	390 395 400
25	Trp Ser Ser Met Thr Pro His Arg His Gln Lys Thr Pro Glu Asn Tyr	
	405	410 415
	Pro Asn Ala Gly Leu Thr Met Asn Tyr Cys Arg Asn Pro Asp Ala Asp	
	420	425 430
	Lys Gly Pro Trp Cys Phe Thr Thr Asp Pro Ser Val Arg Trp Glu Tyr	
30	435	440 445
	Cys Asn Leu Lys Lys Cys Ser Gly Thr Glu Ala Ser Val Val Ala Pro	
	450	455 460
	Pro Pro Val Val Leu Leu Pro Asp Val Glu Thr Pro Ser Glu Glu Asp	
	465	470 475 480
35	Cys Met Phe Gly Asn Gly Lys Gly Tyr Arg Gly Lys Arg Ala Thr Thr	
	485	490 495
	Val Thr Gly Thr Pro Cys Gln Asp Trp Ala Ala Gln Glu Pro His Arg	
	500	505 510
	His Ser Ile Phe Thr Pro Glu Thr Asn Pro Arg Ala Gly Leu Glu Lys	
40	515	520 525
	Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Cys Tyr	
	530	535 540
	Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Cys Asp Val Pro Gln Cys	
	545	550 555 560
45	Ala Ala Pro Ser Phe Asp Cys Gly Lys Pro Gln Val Glu Pro Lys Lys	
	565	570 575
	Cys Pro Gly Arg Val Val Gly Gly Cys Val Ala His Pro His Ser Trp	
	580	585 590
	Pro Trp Gln Val Ser Leu Arg Thr Arg Phe Gly Met His Phe Cys Gly	
50	595	600 605
	Gly Thr Leu Ile Ser Pro Glu Trp Val Leu Thr Ala Ala His Cys Leu	
	610	615 620
	Glu Lys Ser Pro Arg Pro Ser Ser Tyr Lys Val Ile Leu Gly Ala His	
	625	630 635 640

WO 99/16889

- 39 -

PCT/US98/20464

Gln Glu Val Asn Leu Glu Pro His Val Gln Glu Ile Glu Val Ser Arg
 645 650 655
 Leu Phe Leu Glu Pro Thr Arg Lys Asp Ile Ala Leu Leu Lys Leu Ser
 660 665 670
 5 Ser Pro Ala Val Ile Thr Asp Lys Val Ile Pro Ala Cys Leu Pro Ser
 675 680 685
 Pro Asn Tyr Val Val Ala Asp Arg Thr Glu Cys Phe Ile Thr Gly Trp
 690 695 700
 Gly Glu Thr Gln Gly Thr Phe Gly Ala Gly Leu Leu Lys Glu Ala Gln
 10 705 710 715 720
 Leu Pro Val Ile Glu Asn Lys Val Cys Asn Arg Tyr Glu Phe Leu Asn
 725 730 735
 Gly Arg Val Gln Ser Thr Glu Leu Cys Ala Gly His Leu Ala Gly Gly
 740 745 750
 15 Thr Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Phe Glu
 755 760 765
 Lys Asp Lys Tyr Ile Leu Gln Gly Val Thr Ser Trp Gly Leu Gly Cys
 770 775 780
 Ala Arg Pro Asn Lys Pro Gly Val Tyr Val Arg Val Ser Arg Phe Val
 20 785 790 795 800
 Thr Trp Ile Glu Gly Val Met Arg Asn Asn
 805 810

25 <210> 78
 <211> 127
 <212> PRT
 <213> human

<400> 78
 30 Gly Pro Thr Gly Thr Gly Glu Ser Lys Cys Pro Leu Met Val Lys Val
 1 5 10 15
 Leu Asp Ala Val Arg Gly Ser Pro Ala Ile Asn Val Ala Val His Val
 20 25 30
 Phe Arg Lys Ala Ala Asp Asp Thr Trp Glu Pro Phe Ala Ser Gly Lys
 35 35 40 45
 Thr Ser Glu Ser Gly Glu Leu His Gly Leu Thr Thr Glu Glu Glu Phe
 50 55 60
 Val Glu Gly Ile Tyr Lys Val Glu Ile Asp Thr Lys Ser Tyr Trp Lys
 65 70 75 80
 40 Ala Leu Gly Ile Ser Pro Phe His Glu His Ala Glu Val Val Phe Thr
 85 90 95
 Ala Asn Asp Ser Gly Pro Arg Arg Tyr Thr Ile Ala Ala Leu Leu Ser
 100 105 110
 Pro Tyr Ser Tyr Ser Thr Thr Ala Val Val Thr Asn Pro Lys Glu
 45 115 120 125

50 <210> 79
 <211> 18
 <212> PRT
 <213> human

<400> 79
 Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly
 1 5 10 15

WO 99/16889

- 40 -

PCT/US98/20464

Ser Asn

5 <210> 80
 <211> 4
 <212> PRT
 <213> human

 <400> 80
 10 Gly Gly Gly Ser
 1

 <210> 81
 <211> 8
 15 <212> PRT
 <213> human

 <400> 81
 20 Gly Gly Gly Ser Gly Gly Gly Ser
 1 5

 <210> 82
 <211> 12
 <212> PRT
 25 <213> human

 <400> 82
 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1 5 10
 30

 <210> 83
 <211> 7
 <212> PRT
 <213> human
 35

 <400> 83
 Ser Gly Gly Ser Gly Gly Ser
 1 5

 40 <210> 84
 <211> 6
 <212> PRT
 <213> human

 <400> 84
 45 Glu Phe Gly Asn Met Ala
 1 5

 <210> 85
 50 <211> 7
 <212> PRT
 <213> human

 <400> 85

WO 99/16889

- 41 -

PCT/US98/20464

Glu Phe Gly Gly Asn Met Ala
 1 5

5
 <210> 86
 <211> 10
 <212> PRT
 <213> human
 <400> 86

10
 Glu Phe Gly Gly Asn Gly Gly Asn Met Ala
 1 5 10

15
 <210> 87
 <211> 7
 <212> PRT
 <213> human
 <400> 87

20
 Gly Gly Ser Asp Met Ala Gly
 1 5

25
 <210> 88
 <211> 4
 <212> PRT
 <213> human
 <400> 88

30
 Gly Gly Gly Ser
 1

35
 <210> 89
 <211> 5
 <212> PRT
 <213> human
 <400> 89

40
 Gly Gly Gly Gly Ser
 1 5

45
 <210> 90
 <211> 6
 <212> PRT
 <213> human
 <400> 90

50
 Gly Gly Gly Gly Gly Ser
 1 5

<210> 91
 <211> 3
 <212> PRT
 <213> human
 <400> 91

WO 99/16889

- 42 -

PCT/US98/20464

Ala Gly Ser
1

5
 <210> 92
 <211> 7
 <212> PRT
 <213> human

10
 Gly Gly Gly Gly Gly Gly Ser
 1 5

15
 <210> 93
 <211> 36
 <212> PRT
 <213> human

20
 Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly
 1 5 10 15
 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser
 20 25 30
 Gly Gly Gly Ser
 35

25
 <210> 94
 <211> 24
 <212> PRT
 <213> human

30
 <400> 94
 Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Ser Pro Pro
 1 5 10 15
 Ser Lys Glu Ser His Lys Ser Pro

35
 20

40
 <210> 95
 <211> 28
 <212> PRT
 <213> human

45
 <400> 95
 Ile Glu Gly Arg Ile Ser Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn
 1 5 10 15
 Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro
 20 25

50
 <210> 96
 <211> 28
 <212> DNA
 <213> human

<400> 96
 catgccatgg cagtgtatct ctccagtgc

WO 99/16889

- 43 -

PCT/US98/20464

5 <210> 97
 <211> 30
 <212> DNA
 <213> human

 <400> 97
catgccatgg cagtttatct ttcagagtgt 30

10 <210> 98
 <211> 34
 <212> DNA
 <213> human

15 <400> 98
gatcaagctt ttattaagcc aattgttccg tgga 34

20 <210> 99
 <211> 34
 <212> DNA
 <213> human

 <400> 99
gatcaagctt ttattacgct tctgttcctg agca 34
25

 <210> 100
 <211> 34
 <212> DNA
 <213> human
30

 <400> 100
gatcaagctt ttattaaagc aggacaacag gcgg 34

35 <210> 101
 <211> 48
 <212> DNA
 <213> human

 <400> 101
40 gatcacatgt chgargarga rtgyatgcay tgcagtggag aaaactat 48

 <210> 102
 <211> 48
 <212> DNA
45 <213> human

 <400> 102
gatcacatgt chgtbtayct btchgartgy aagactggga atggaaag 48

50 <210> 103
 <211> 48
 <212> DNA
 <213> human

WO 99/16889

- 44 -

PCT/US98/20464

	<400> 103	
	gatcacatgt chctbtttyga raaraargtb tatctctcag agtgcaag	48
5	<210> 104	
	<211> 34	
	<212> DNA	
	<213> human	
10	<400> 104	
	gatcggatcc gccaccatgg aacataagga agtg	34
	<210> 105	
	<211> 31	
15	<212> DNA	
	<213> human	
	<400> 105	
	gatcggatcc ttaatcaaatt gaagggggccg c	31
20	<210> 106	
	<211> 25	
	<212> DNA	
	<213> human	
25	<400> 106	
	gatcccatgg cagtgtatct gtccg	25
	<210> 107	
	<211> 40	
30	<212> DNA	
	<213> human	
	<400> 107	
35	gatcaagctt tccagactcg agcgcttctg ttcctgagca	40
	<210> 108	
	<211> 27	
	<212> DNA	
	<213> human	
40	<400> 108	
	tgtccatcac cgtggtagca gtcctgg	27
	<210> 109	
45	<211> 33	
	<212> DNA	
	<213> human	
	<400> 109	
50	tgccatacaa cgaattccca agtgcggtgg gag	33
	<210> 110	
	<211> 30	
	<212> DNA	

WO 99/16889

- 45 -

PCT/US98/20464

<213> human
 <400> 110
 catgccatgg cagtttatct ttcagagtgt 30
 5
 <210> 111
 <211> 34
 <212> DNA
 <213> human
 10
 <400> 111
 gatcaagctt ttattattcc ttttcacact caag 34
 <210> 112
 <211> 281
 <212> DNA
 <213> human
 15
 <400> 112
 20 ccatggcagt ttatctttca gagtgtgaaga ctgggaatgg aaagaattac agagggacga 60
 tgtccaaaac aaaaaatggc atcacctgtc aaaaatggag ttccacttct cccacagac 120
 ctagattctc acctgctaca caccctcag agggactgga ggagaactac tgcaggaatc 180
 cagacaacga tccgcagggg ccttgggtgt atactactga tccagaaaag agatatgact 240
 actgcgacat tcttgagtgt gaagaggaat aataaaagct t 281
 25
 <210> 113
 <211> 89
 <212> PRT
 <213> human
 30
 <400> 113
 Met Ala Val Tyr Leu Ser Glu Cys Lys Thr Gly Asn Gly Lys Asn Tyr
 1 5 10 15
 Arg Gly Thr Met Ser Lys Thr Lys Asn Gly Ile Thr Cys Gln Lys Trp
 20 25 30
 Ser Ser Thr Ser Pro His Arg Pro Arg Phe Ser Pro Ala Thr His Pro
 35 40 45
 Ser Glu Gly Leu Glu Glu Asn Tyr Cys Arg Asn Pro Asp Asn Asp Pro
 50 55 60
 40 Gln Gly Pro Trp Cys Tyr Thr Thr Asp Pro Glu Lys Arg Tyr Asp Tyr
 65 70 75 80
 Cys Asp Ile Leu Glu Cys Glu Glu Glu
 85

Claims

WHAT IS CLAIMED IS:

1. A multi-functional protein, comprising an amino acid sequence of the
5 formula:

$$\begin{array}{l} R_1-L_1-R_2; \\ R_2-L_1-R_1; \\ R_1-L_1-R_1; \\ R_1-R_2; \\ 10 R_2-R_1; \text{ and} \\ R_1-R_1; \end{array}$$

wherein R_1 is angiostatin;
and R_2 is selected from endostatin, human type I interferon, thrombospondin, interferon-inducible protein 10 (IP-10), and platelet factor
15 4;
and wherein L_1 is a linker capable of linking R_1 to R_2 ;
and said protein can optionally be immediately preceded by (methionine⁻¹), (alanine⁻¹), (methionine⁻², alanine⁻¹), (serine⁻¹), (methionine⁻², serine⁻¹), (cysteine⁻¹), or (methionine⁻², cysteine⁻¹).

20
2. The multi-functional protein as recited in claim 1, wherein R_1 is selected from the group consisting of angiostatin K1, angiostatin K1-K3, angiostatin K1-K4, angiostatin K1-K5, angiostatin K5, and a functional homologue thereof.
- 25 3. The multi-functional protein as recited in claim 1, wherein said type I interferon is selected from the group consisting of type I interferon variants, interferon alpha 2a, interferon alpha 2b, interferon alpha hybrid A/D, consensus interferon, and a functional homologue thereof.
- 30 4. The multi-functional protein as recited in claim 1, 2, or 3 wherein said linker (L_1) is one or more peptide sequences selected from the group consisting of;
SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID
35 NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, and a functional homologue thereof.

5. The multi-functional protein of claim 1, wherein the amino acid sequence is selected from the group consisting of
SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID
NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61,
SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID
NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70,
SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID
NO:75,
or a functional homologue thereof.
6. Use of a multi-functional protein fragment of claim 1 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
7. Use of a multi-functional protein fragment of claim 2 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
8. Use of a multi-functional protein fragment of claim 3 for the manufacture of a medicament for therapeutic application to inhibit tumor growth.
9. A nucleic acid molecule encoding said multi-functional protein of claim 1.
10. A nucleic acid molecule encoding said multi-functional protein of claim 2
11. A nucleic acid molecule encoding said multi-functional protein of claim 3.
12. A nucleic acid molecule encoding said multi-functional protein of claim 1, wherein said nucleic acid sequence is selected from the group consisting of
SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID
NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35,
SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID
NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44,
SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID
NO:49,
or a combination or a functional homologue thereof.
13. A method of producing a multi-functional protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 9, 10,

11, or 12 in a manner allowing expression of said multi-functional protein and recovering said multi-functional protein.

- 5 14. A pharmaceutical composition comprising a therapeutically effective amount of the multi-functional protein according to claim 1, 2, or 3 and a pharmaceutically acceptable carrier.
- 10 15. The pharmaceutical composition of claim 14 further comprising an adjunctive agent, wherein said adjunctive agent is selected from the group consisting of chemotherapeutic and immunotherapeutic agents.
- 15 16. A method of treating a human patient with an angiogenic-mediated disease, comprising administering to the patient with an angiogenic-mediated disease an effective amount of multi-functional protein of claim 1.
17. The method of claim 16, wherein the angiogenic-mediated disease is selected from the group consisting of cancer, diabetic retinopathy, macular degeneration, and arthritis.
- 20 18. A method of modulating tumors in a patient comprising the step of; administering an effective amount of the multi-functional protein as recited in claim 1, 2, or 3 to said patient.
- 25 19. A method of inhibiting the production of tumor cells in a patient comprising the step of administering an effective amount of the multi-functional protein as recited in claim 1, 2, or 3 to said patient.
- 30 20. The method of claim 19, wherein the tumor cell is characteristic of one selected from the group consisting of lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.
- 35 21. A method for treatment of a patient having a solid tumor, comprising the steps of;
(a) measuring tumor size;
(b) administering an effective dose of multi-functional protein in a vehicle;
and

(c) periodically monitoring reduction in tumor size.

- 5 22. A method of human gene therapy, comprising delivery of a gene delivery vehicle to cells in or adjacent to a tumor, said vehicle encoding a multi-functional protein.
23. A method of claim 22, wherein said vehicle is a vector comprising a nucleic acid encoding a polypeptide capable of inhibiting tumor growth.
- 10 24. A method of claim 22, wherein said multi-functional protein is selected from the group of proteins as recited in claim 1, 2, 3, 4, or 5.
25. A gene therapy vector comprising a nucleic acid encoding a polypeptide capable of inhibiting tumor growth.
- 15 26. A composition consisting of a therapeutically effective dose of a nucleic acid encoding a polypeptide capable of inhibiting tumor growth in a physiologically tolerable diluent.
- 20 27. A gene therapy vehicle of claim 26 that is lyophilized.
28. A gene therapy vehicle of claim 26 that is dehydrated.

FIG. 1

Selected cloned angiostatin fragments containing kringle domains preceded by an IL-3 signal peptide

Angiostatin fragments






FIG.2

Selected cloned angiostatin fragments containing kringle domains

Angiostatin fragments



3 / 4

FIG.3Selected angiostatin/interferon alpha chimeric fusion proteins

4 / 4


FIG.4Selected angiostatin/interferon alpha A/D chimeric fusion proteins

Figure 5

***Proliferation of Daudi cells in the presence of interferon A/D
and an interferon A/D K1-3 angiostatin chimeric protein***

ANY REFERENCE TO FIGURE 5 SHALL BE CONSIDERED NON-EXISTENT